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ABSTRACT 
 
 
 Identification of genetic risk factors associated with the development of secondary 
cancers would facilitate identification of at risk patients and permit modification of 
therapy and heightened surveillance that may reduce cancer-related morbidity and 
mortality. Women survivors of pediatric Hodgkin lymphoma (HL) have an increased risk 
of morbidity and mortality associated with secondary effects of therapy, with a 35-75 fold 
excess risk of developing breast cancer over the general population. The mechanism for 
secondary breast cancer among Hodgkin survivors is not understood. Researchers have 
postulated that the familial characteristics of HL could be associated with mutations 
found within familial cancer syndromes; however, these mutations have not been 
identified. This has led to the exploration of inherent polymorphisms that might impair 
the patient’s capability to detoxify chemotherapy and/or repair DNA damage produced 
by irradiation. Examinations of candidate polymorphisms indicate that single nucleotide 
changes may have only a small effect on the development of subsequent cancers. 
However, multiple studies support the idea that sensitivity to irradiation and the 
subsequent development of breast cancer is mediated through the interaction of multiple 
genes or gene complexes. The objective of this case-control study design was to explore 
the identification of potential candidate genes and polymorphisms that may be risk 
factors for the development of secondary breast cancer among women who are pediatric 
HL survivors. Global gene expression and genotyping of women with (n=13) and without 
(n=36) secondary breast cancer after the treatment of pediatric HL were compared. 
Differences were found in global gene expression and genotyping between the cases and 
controls. Additionally, copy number variation in association with gene expression found 
a locus of interest at 15q11.2 in association with the development of secondary breast 
cancer.   
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CHAPTER 1. INTRODUCTION 
 
 
Problem 
 
Overall survival of pediatric Hodgkin lymphoma (HL) is 90%; however, due to 
late treatment complications including subsequent malignancy, survival decreases with 
time [1, 2] . Women survivors of pediatric HL have an increased morbidity and mortality 
associated with secondary effects of therapy, most specifically those associated with 
radiation [3-6]. It is estimated that the relative risk of breast cancer among HL women 
survivors treated prior to 30 years of age is 6 to 17-fold [7-9], with the largest relative 
risk ranging from 60-fold to 112-fold for those treated at 16 years of age or younger  [7, 
8, 10]. Furthermore, these women have reached a 12.9% cumulative incidence of breast 
cancer by 40 years of age [3], and at 50 years of age many HL survivors treated with 
chest radiation have exceeded the lifetime risk of developing breast cancer as compared 
to the general population which is a 13.4 % lifetime cumulative incidence, one in eight 
women [11, 12]. The relative risk for secondary breast cancer is highest at 15 to 20 years 
after initial HL radiation [3, 5, 7], while an increased cumulative absolute risk of breast 
cancer reflects background breast cancer associated with increasing age [11]. In 
comparison to other high risk breast cancer groups such as BRCA1 and BRCA2 carriers, 
women treated for HL at a young age with radiation therapy and without alkylating 
agents may only have a modestly smaller risk than the high risk carriers of the BRCA 
mutation [11]. Therefore, women HL survivors are at a significantly high risk for the 
development of breast cancer and remain so throughout their lifetime.  
 
The mechanism for early age on-set breast cancer among Hodgkin survivors is not 
understood; however, specific characteristics have been identified as being risk factors 
and include: age at the time of HL diagnosis[3, 5-7, 11, 13, 14], radiation exposure[5, 7, 
11, 13-16], endocrine function[13, 14], and familial cancer history [3]. Studies show that 
other risk factors such as administration of combined modality therapy [7], alkylating 
agents [3, 13, 14, 17], pelvic radiation [13], pregnancy, and use of hormonal therapy have 
conflicting associations to secondary breast cancer among HL survivors. 
 
In attempting to better understand the mechanism of secondary breast cancer, 
researchers have postulated that the familial characteristics of HL and high incidence of 
secondary breast cancer may result from mutations similar to those identified in inherited 
breast cancer syndromes. To date, inherited mutations such as TP53, BRCA1, BRCA2, 
and heterozygous ATM mutations have not been identified among HL survivors with 
secondary breast cancer [3, 18, 19]. While many of the associated risk factors of 
secondary breast cancer are well documented, there have been no association studies that 
have linked an identified genetic risk factor marker.  
 
Failure to identify commonly inherited mutations or markers has led to the 
exploration of inherent polymorphisms that might impair the patient’s capability in 
detoxification of chemotherapy and/or repair of deoxyribonucleic acid (DNA) damage 
produced by radiation  [20, 21]. Examination of these candidate polymorphisms has 
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found that single nucleotide changes may have only a small effect on the development of 
subsequent cancers and the strongest effect on secondary cancer development is perhaps 
a gene-gene interaction. This is evident in studies that support the idea that sensitivity to 
radiation and the subsequent development of breast cancer is mediated through the 
interaction of multiple genes or gene complexes [18, 19, 21]. 
 
Thus far, the association of candidate genes and polymorphisms and the 
development of secondary breast cancer have not been found. To my knowledge, there 
has not been a whole genome association study examining the global gene expression and 
single nucleotide polymorphisms associated with HL and secondary breast cancer. To 
explore the genetic contribution to this complex disease, the purpose of this study was to 
identify gene expression patterns and candidate polymorphisms that may be risk factors 
for the development of secondary breast cancer. Study methods focused on identifying 
differential gene expressions between two groups of women who are pediatric HL 
survivors; those who developed secondary breast cancer (case) and those who have not 
(control) developed secondary breast cancer within 20 years after HL diagnosis. 
Individual global gene expression was characterized and associated with their expressed 
polymorphism (mutation). The gene expression was measured by microarray analysis and 
an association study correlated the genotypes at 500,000 single nucleotide polymorphism 
(SNP) loci with the gene expression levels. The study also examined gene and 
polymorphism expression differences between the case and controls and identified global 
gene expression and the associated genotype copy number variation among the cases and 
controls. Association data will provide candidate genes, polymorphisms and a region of 
copy number variation for consideration in the etiology of secondary breast cancer after 
HL therapy. Furthermore, identification of genes, polymorphism, and copy number 
variations associated with the development of secondary cancers would facilitate 
identification of at risk patients and permit modification of therapy and heightened 
surveillance that may reduce cancer-related morbidity and mortality. 
 
 
Primary Aims 
 
 The primary aims were to: 
 
1. Assess whether global gene expression profiles differ between two groups of 
radiated pediatric female HL survivors with (cases) and without (controls) the 
development of secondary breast cancer.  
 
1.1.  Identify the gene expression profile for cases 
1.2.  Identify the gene expression profile for controls 
1.3.  Identify the gene expression profile similarities and differences between  
cases and controls 
 
2. Assess whether genotype profiles differ between two groups of radiated pediatric 
female HL survivors with (cases) and without (controls) the development of 
secondary breast cancer.  
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 2.1. Identify the genotype profile for cases 
2.2.  Identify the genotype profile for controls 
2.3. Identify the genotype profile similarities and differences between cases  
and controls  
 
3. Identify potential candidate genes through identifying copy number variations that 
associate with the risk of secondary breast cancer.   
 
 The secondary aim was to explore the associations among lifestyle characteristics 
(hormone use, pregnancy, lactation), family history and the occurrence of breast cancer.  
 
 
Significance 
 
According to the American Cancer Society, over 7,000 new cases of HL were 
diagnosed in 2005 with 10-15% of these cases occurring in children 16 years and younger 
[22]. With the combination of chemotherapy and radiation, the 5-year survival for those 
with low stage disease is 85-95% and 70-90% survival for those with advanced disease 
[12]. The intensity of therapy is stage-related.  
 
With improved therapy it is now estimated that among the general population 1 of 
every 300 young adults < 45 years of age is a survivor of childhood cancer [22]. 
Furthermore, cancer survivors of all ages comprise 3.5% of the United States population. 
Although these individuals have survived cancer, they are at greater risk for subsequent 
cancers. Approximately 16% of the annual cancer incidence occurs as a second cancer in 
a cancer survivor  [23]. One of the most devastating event for any cancer survivor is the 
occurrence of a second cancer, but particularly devastating is the second cancer for a 
young adult who is starting a career and family.  As cancer survival rates increase so will 
the number of survivors who will experience a secondary cancer. 
 
Recently, there has been an increased interest and concern regarding the health 
status and late effects associated with childhood cancer care, most specifically the late 
effect of secondary cancers. Studies have found one of the highest occurrences of second 
cancers is among women who are HL survivors [3, 4, 6, 7]; therefore, it is of importance 
that factors contributing to secondary cancers in this group be identified.  
 
While environmental risk factors such as radiation have been identified, inherent 
risk factors are just beginning to be studied. Identification of secondary breast cancer 
inherent risk factors could provide an at risk patient profile at the time of initial diagnosis. 
This profile would be important when considering therapeutic agents that may be added 
or deleted in the initial treatment of HL resulting in a reduction of late effects. Lastly, one 
could foresee the high risk profile individual being counseled, screened, and offered 
preventive therapies such as those of known breast cancer risk associated with BRCA1 
and BRCA2 gene mutation.  
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The primary focus of this study was to begin the development of an inherent 
genetic risk patient profile. Thus far the candidate gene approach has not found evidence 
of known inherited mutations among those with secondary breast cancer [3, 18, 19]. 
Therefore, this study explored the comparison between an individual’s genotype in 
consideration of treatment variables that may contribute to the increased incidence of 
secondary breast cancer among HL survivors compared to non-secondary breast cancer 
HL survivors. This study took advantage of rapidly evolving biotechnology in gene 
profiling and genotyping using microarray technology. The global gene expression and 
genotypes of HL survivors with breast cancer was explored to identify potential candidate 
polymorphisms associated with genotype allele frequency and the possible contribution 
of the genotype to the development of secondary breast cancer. Identification of potential 
polymorphisms will be valuable in the development of future research projects in 
replication and validation within larger samples of HL survivors with secondary breast 
cancer.  
 
Gene profiling and genotyping technology is quickly advancing and showing 
significant progress in the identification of prognostic indicators for complex disorders. A 
number of studies have identified prognostic and predictive ‘gene’ signatures as 
prognostic indicators in the treatment of breast cancer [24]. Most of the early work with 
microarray analysis and primary breast cancer has been done with tumor samples taken at 
the time of breast surgery. These analyses have enabled researchers to analyze breast 
tissue and obtain a better understanding of the molecular characteristics and clinical 
behavior of breast cancer. This has been most helpful in the analysis of gene 
amplification and coamplification in prognosis and treatment of breast cancer [25]. While 
tissue study is beneficial in determining prognosis and treatment response, molecular 
expression from a tumor sample presents difficulty in determining the causality of the 
tumor due to both primary and secondary chromosomal changes. Primary changes are 
present in all tumor cells, while secondary changes are associated with revascularization 
or the development of metastatic disease [26]. Examination of breast tissue will give 
expression at the site of the disease and reflect the characteristics of the individual tumor, 
but will not give a global picture of the gene interaction that may have predisposed an 
individual to cancer. With the hypothesis that the second cancer is the result of an 
inherent gene-gene/environment interaction, breast tissue would not reflect inherent or 
germline expression. Therefore, this study will explore the use of peripheral blood as a 
potential predictor of germline genetic risk for the occurrence of secondary breast cancer.     
       
Lastly this study is significant for its interdisciplinary approach. Nurses can play a 
pivotal role in the era of genomic research through their skill of design, interdisciplinary 
interaction in completing the methodology and analysis, and the nurses’ skill of research 
dissemination with translation into practice. The nurse-patient rapport provides an 
excellent navigational environment for the nurse to describe genomic screening, provide 
a clear translation of the findings, as well as the implications for treatment decision 
making and follow-up. It is also imperative that the patient have an update family history 
with particular emphasis on family history of cancer and most specifically breast cancer.  
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Conceptual Model 
 
This study evaluated the similarities and differences in genotype allele frequency 
and the associated global gene expression between individuals treated for pediatric HL 
with and without the development of secondary breast cancer. The conceptual model (see 
Figure 1.1) depicts an individual with diagnosed HL involving the mediastinum. The 
standard HL therapy is combination chemotherapy and radiation at the site of disease. 
With the presence of mediastinal HL, most individuals receive radiation therapy to the 
mediastinum disease. At the initiation of treatment, each individual has inherent 
characteristics including familial inherited characteristics and individual genetic 
differences within their individual nucleotide sequence known as polymorphisms.  In 
addition, each individual has specific treatment related risk factors. These risk factors 
include: age at HL diagnosis[3, 5-7, 11, 13, 14], dose of mediastinal radiation [5, 7, 11, 
13-16], administration of alkylating agents [3, 13, 14, 17] and pelvic radiation [13].  
During the therapeutic administration of mediastinal radiation there is an interaction 
between the inherent and treatment characteristics (gene-environment interaction). Both 
the case and control have ablation of Hodgkin tumor, but the case will have retention 
and/or disrepair of mutated deoxyribonucleic acid (DNA) within the non-diseased breast 
tissue. The control group will have repair and/or apoptosis of mutated DNA in the non-
disease breast tissue. Overtime, both groups will undergo additional genetic insults from 
exposures within the individuals’ environment. For each case, penetrance of secondary 
breast cancer is dependent upon persistent and additional somatic mutations [27].  As a 
result of the retained mutated DNA and successive mutations, the secondary cancer will 
occur approximately 15-20 years after the initial DNA mutation initiated by radiation [3, 
7, 8]. 
 
Determining the genotype differences among the cases and controls was 
accomplished through the technology of DNA and expression microarray. The human 
genome is made of 3 billion base pairs with single nucleotide polymorphisms (SNPs) 
noted between individuals at every 1000 base pairs. Furthermore, it is these 
polymorphisms that give “biochemical individuality” among the human species [28]. 
With the interaction of one’s biochemical pathways (gene-gene interaction), regardless of 
one’s state of health, there is a genetic predetermined chemical individuality that 
responds to environmental and pharmacological influences (gene-environment) [28]. 
 
Microarray technology has predominantly been utilized in the analysis of 
expressed genes within and between biologically matched subjects; however, with human 
genome mapping they can now be utilized for study of genetic variations among 
individuals and referred to as SNP analysis. SNP analysis is useful in linkage analysis for 
identification of disease markers, loss of heterozygosity (LOH), uniparental disomy, for 
analysis of tumor suppressor genes, and association studies to link SNPs to overly or 
underly expressed genes [29]. Therefore, this proposal utilized whole genome analysis of 
gene expression and genotyping at polymorphic sites between cases and controls. The 
gene expression was analyzed from the extracted RNA, while genotyping (SNP) data 
were analyzed from the extracted DNA.    
6 
 
 
 
Figure 1.1 Conceptual Model Describing the Events Following Mediastinal Radiation in 
Case and Control, with the Utilization of Gene and Genotype Expression as a Predictor. 
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The goal of the study was to acquire an enhanced understanding of the biological 
pathway leading to the development of secondary breast cancer, and identification of 
potential biomarkers that may identify women at risk. It is hypothesized that genetic 
differences between the case and control are responsible for a differential response to 
initial DNA damage. Accumulation of DNA mutations at different rates would lead to 
early onset of secondary breast cancer. The gene expression and genotype profiles were 
compared between cases and controls as well as the copy number variation. This analysis 
identified potential candidate genes and a site of deletion for consideration in the etiology 
of secondary breast cancer. Once women are identified as being at risk, treatment may be 
modified for prevention of therapy related morbidity/mortality thereby improving quality 
of life. 
 
 
Definition of Terms 
 
• Hodgkin lymphoma (HL): Participants within this study, both cases and 
controls, were diagnosed with HL prior to 25 years of age.  The diagnosis of HL 
was based upon pathological examination of lymph node tissue and documented 
in the medical record. 
• Case (Secondary Breast Cancer): Participants classified as cases were surviving 
women who were treated for pediatric HL with mediastinal radiation and 
subsequently developed breast cancer prior to 50 years of age. The diagnosis of 
secondary breast cancer is based on pathology examination and documented in 
the medical record. 
• Control (Non-Secondary Breast Cancer): Participants classified as controls 
were surviving women who were treated for pediatric HL with medialstinal 
radiation and have not developed any subsequent cancer. These women will have 
a negative mammogram within one year of the study and a negative history for 
proliferative breast disease. This data was obtained through participant reporting.   
• Copy Number Variation: Copy number variation gives the number of DNA 
segments within the genome. It was thought that genes were present in two copies 
but is now known that there is variability and DNA segments may be lost or 
gained. This gives an insight into the variability among individuals and may 
contribute to disease. 
• Genotype: Genotype is an individuals’ set of alleles that make up ones genetic 
constitution, either collectively or at a single locus. This study explored 
differences in genotypes using single nucleotide polymorphisms. 
• Phenotype: Phenotype is the observable characteristics of an individual, resulting 
from the interaction of the genotype and environment.  
• Single Nucleotide Polymorphism (SNP): Single nucleotide polymorphisms are 
found throughout an individual’s genotype and may affect phenotype. A SNP is a 
DNA marker and designates differences in the DNA sequence of homologous 
chromosomes. For the DNA differences to be termed a SNP, they must be present 
in more than 1% of the population [30]. The genotype expression, the presence of 
single nucleotide polymorphisms (SNP), was measured with the Affymetric 
GeneChip® Human Mapping 500K Set.  
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• Gene Expression: Gene expression is the process of transcription of DNA into 
messenger ribonucleic acid (mRNA) and translation of the mRNA into protein. 
This study will assess an individuals’ gene expression and the association of this 
expression to the genotype. The differences in global gene expression between 
cases and controls will be measured with the Affymetrix GeneChip® Human 
Genome U133 Plus 2.0 Array.  
• Microarray: Microarray analysis allows genomic measurement of an individual’s 
gene expression under a variety of genetic and environmental conditions. The 
mRNA is reverse transcribed to complimentary DNA (cDNA) and labeled with 
fluorescent dyes and hybridized to the microarray glass slide. The glass slide has 
oligonucleotides arranged in columns and rows which are constructed for a 
specific gene. Lasers are then used to generate an image from the sample. The 
data are expressed in a matrix with columns indicating samples and rows 
indicating genes [31]. The Affymetrix GeneChip® Human Genome U133 Plus 
2.0 Array will analyze gene expression. Microarray technology also has the 
application for detection of polymorphisms within an individuals’ genome. The 
DNA is labeled with fluorescent dyes and hybridized to the microarray. The array 
has oligonucleotides that are associated with 500,000 known SNPs within the 
genome. This study will use the Affymetric GeneChip® Human Mapping 500K 
Set for SNP analysis.  
• Gene-Environment Interaction: A gene to environment interaction occurs when 
the environmental effects on phenotype differ according to the individual 
genotype.  
• Gene-Gene Interaction: The regulated expression of genes is dependent upon 
complex interrelationships among genes within the genome. Changes within this 
interrelationship among genes can significantly affect biological pathways [28]. 
 
 
Assumptions 
 
1. Women diagnosed with pediatric HL are a vulnerable host for recurrent 
malignancies. 
2. HL survivors with and without breast cancer have a genetic predisposition that 
responds differently to radiation exposure. 
3. The gene expression profile between the cases and controls may not differ due to 
cumulative absolute risk of breast cancer among controls due to background 
breast cancer associated with increasing age. 
4. The identified gene pathways will direct future research in the study of candidate 
genes that had not been previously considered.  
5. Ultimately, identification of polymorphisms and copy number variation could be 
integral in the development of a predictive model for those at risk of secondary 
breast cancer.  
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Potential Limitations 
 
1. Much research has focused on the genetic study of primary breast cancer; 
however, these data may not be generalizable to other breast cancer patients. Most 
breast cancer research has focused on the genetic characteristics of the tumor, 
while this study will focus on the inherent individual characteristics that 
predispose one to the development of breast cancer. 
2. Secondary breast cancer is most often diagnosed 15-20 years after the initial HL 
diagnosis; however, this will vary among individuals [3, 7, 8]. All controls will 
have undergone the passage of 15 to 20 years since diagnosis and will be matched 
with the cases on time since diagnosis; however, a control could become a case 
during the course of the study. 
3. Blood samples for gene expression were collected at outlying physician’s offices 
and mailed to a designated lab for RNA extraction. If collection, storage, and 
mailing were not completed as instructed, there may have been degradation of the 
RNA in transport. If RNA degradation occurs, there may be loss of transcripts and 
gene expression. However, each sample will undergo a quality control analysis 
before processing and another RNA sample will be submitted if needed.  
4. Methods are available to compute power and sample size for most gene 
expression microarray studies [32]. However, power and sample size calculations 
were not used to design this study due to the limited number of cases. Thus, the 
statistical power to find meaningful associations may be quite low. 
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CHAPTER 2. REVIEW OF LITERATURE 
 
 
Hodgkin Lymphoma 
 
In 1832, Thomas Hodgkin published a paper entitled, “On Some Morbid 
Appearances of the Absorbent Glands and Spleen” describing lymph node and spleen 
enlargement in what came to be known as Hodgkin lymphoma [33]. At the turn of the 
century, diagnosis was dependent upon the microscopic morphology of tissue and 
Hodgkin tumors were recognized to have abnormally giant cells. These giant cells were 
first described by Sternberg [34] and Reed [35] who were credited with describing HL 
histopathology, hence the naming of the Reed Sternberg cells found within HL tumor.   
 
Until recently the malignant cell of HL origin has remained unknown. New 
technologies such as polymerase chain reaction (PCR) and micro laser dissection have 
assisted in determining clonal immunoglobulin rearrangements and the origin of 
malignancy as B-lymphoid cells [36, 37]. The World Health Organization (WHO) has 
now renamed Hodgkin disease to Hodgkin lymphoma reflecting an understanding of its 
B-cell origin [38]. 
 
It is estimated that only a small portion (0.1% to 10%) of the HL tumor is 
malignant [38]. HL tumors are primarily comprised of inflammatory cells including 
lymphocytes, neutrophils, eosinophils, histiocytes, plasma cells and fibrosis. The 
malignant cells found in HL are the Reed-Sternberg cell and mononuclear/multinucleated 
variants. The Reed-Sternberg cell is a large binuclei or binuclear lobe cell and within 
each of the nuclear lobes are large eosinophilic nucleoli larger than neighboring 
lymphocytes. HL cells may also be highly pleomorphic creating difficulty with diagnosis 
and a differential to include high-grade sarcomas and diffuse large cell lymphomas with 
anaplastic features [39]. 
 
 
Histological Subsets 
 
The WHO classification recognizes two major subsets of HL, classical Hodgkin 
and nodular lymphocyte predominant Hodgkin [38]. This classification is based on the 
tumor morphology and immunophenotype. Classical Hodgkin is categorized into four 
subsets and includes: nodular sclerosis subtype, mixed cellularity subtype, lymphocyte-
rich subtype, and lymphocyte depleted subtype. All subtypes of HL are equally 
responsive to treatment [39]. 
 
 
Hodgkin Staging 
 
In 1971, the Ann Arbor staging for HL was developed, this staging was based on 
the knowledge that HL progressed along lymph node chains [40]. Substage classification 
is also determined at diagnosis according to clinical symptoms at presentation and 
includes A, B, and E substage. At presentation, the history includes notation of 
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constitutional symptoms which include fever >38º c for 3 consecutive days, drenching 
night sweats, and weight loss of ? 10% of body weight over the previous 6 months. Upon 
presentation, a patient without these symptoms is classified as an A substage; however, if 
these symptoms are present they are classified as B substage. Patients with E substage 
have extralymphatic extension of disease directly from nodal disease. The Ann Arbor 
Staging Classification of HL is described in Table 2.1.  
 
 
Hodgkin Lymphoma Therapy 
 
Radiotherapy was the first effective treatment for HL, providing high doses of 
radiation to large fields. Then in 1964, a four-drug regime (MOPP) was introduced as the 
first effective systemic therapy for HL. The MOPP regime includes mechlorethamine 
(nitrogen mustard), Oncovin (vincristine), procarbazine, and prednisone. This regimen 
resulted in a prolonged disease free survival in more than 50% of adult and pediatric 
patients. However, the treatment was found to have significant late effects including 
acute myeloid leukemia (AML) and infertility. To reduce the risk of AML, another 
alkylating agent, cyclophosphamide (COPP) was substituted for mechlorethamine. In 
1970, the ABVD (Adriamycin (Doxorubicin), bleomycin, vinblastine, and dacarbazine) 
regimen was introduced and did not have the associated late effects of AML and 
infertility. While this regimen has led to superior outcomes in adults, the regimen has 
been of concern in pediatrics due to the risk of cardiopulmonary toxicity. Through the 
1980’s, this combined approach of multi-agent chemotherapy and extended volume 
radiation delivered at standard dose of 35-44 Gray (Gy) was the treatment of choice [39]. 
Overtime, significant late effects were noted in HL survivors as a result of the radiation. 
These late effects resulted in investigating the effectiveness of combined multi-agent 
chemotherapy with low dose involved-field radiation delivered at the dose of 15-25.5 Gy 
[41, 42].  
 
In the 1990’s, investigators found that multi-agent chemotherapy with low dose 
radiation did not compromise disease-free survival. Children and adolescents are now 
treated for HL with risk-adapted, combined-modality therapy using multiagent 
chemotherapy and low-dose involved field radiation [39]. For children with low-stage, 
nonbulky disease, chemotherapy alone is being investigated [39]. The objective of risk 
adapted therapy is to provide disease-free survival with minimization of treatment-related 
sequelae including musculoskeletal deformity, cardiopulmonary, and second malignancy.  
 
 
Hodgkin Lymphoma Therapy of Cases and Controls 
 
The cases and controls for this study were treated at St. Jude Children’s Research 
Hospital (SJCRH) between 1970 and 1991, according to institutional protocol. These 
protocols included: HOD 68, HOD 72, HOD 80, and HOD 90. During the years 1969-
1972, HL patients were treated according to the HOD 68 protocol. This protocol 
delivered combined chemotherapy agents; cyclophosphamide, vincristine +/- 
procarbazine and prednisone plus radiation therapy at doses ranging from 35-44 Gy 
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Table 2.1 Ann Arbor Staging Classification. 
 
Stage Definition 
I (A/B) 
Involvement of a single lymph node region (I) or of a single  
extralymphatic organ or site (IE) 
II (A/B) 
Involvement of two or more lymph node regions on the same side of 
the diaphragm (II) or localized involvement  of an extralymphatic 
organ or site and one or more lymph node regions on the same side of 
the diaphragm (IIE) 
III (A/B) 
Involvement of lymph node regions on both sides of the diaphragm 
(III), which may be accompanied by involvement of the spleen (IIIS) or 
by localized involvement of an extralymphatic organ or site (IIIE) or 
both (IIISE) 
IV (A/B) 
Diffuse or disseminated involvement of one or more extralymphatic 
organs or tissues with or without associated lymph node involvement 
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delivered to extended volume fields. The HOD 72 protocol was opened in 1972-1980 and 
compared standard dose radiation therapy at doses 35-44 Gy alone to radiation therapy at 
doses 35-44 Gy plus chemotherapy agents cyclophosphamide, vincristine, procarbazine, 
and prednisone (COPP).  The HOD 80 protocol was opened in 1980-1984 and combined 
chemotherapy COPP with lower dose radiation at 20 Gy extended-volume. In 1984-1990, 
the HOD 80A protocol was open and continued utilization of lower dose radiation at 20 
Gy; however, the radiation was delivered to only the field of disease involvement. 
Alternating cycles of chemotherapy were administered and included COP(P) and ABVD. 
 
Prednisone was only administered to patients with “B” symptoms. HOD 90 was 
opened in 1990 and was the first protocol to classify patients according to risk. The low 
risk arm therapy consisted of 4 cycles of vinblastine, adriamycin, methotrexate, and 
prednisone (VAMP) and low dose involved field radiation delivered between 15-25.5 Gy. 
The radiation dose was determined according to disease response after two cycles of 
VAMP. High risk patients received 6 cycles of chemotherapy which included vincristine, 
etoposide, prednisone, and adriamycin (VEPA) followed by 25.5Gy radiation therapy. 
Radiation therapy was not initiated until after the second cycle of chemotherapy except 
for patients with extensive disease who began radiation after the completion of all 
chemotherapy. Patients that required more than one treatment field of radiation received 
the later courses of radiation after the fourth or sixth course of chemotherapy.  
      
 
Secondary Malignancy 
 
Children and adolescents treated for HL have a higher incidence of long-term late 
effects secondary to treatment when compared to other childhood cancer survivors [1, 11, 
41]. One of the devastating late effect for any cancer survivor is the occurrence of a 
second cancer. A large HL cohort followed for 27.8 years found the estimated cumulative 
incidence of any second cancer was 10.6% at 20 years and increasing to 26.3% at 30 
years. The estimated cumulative incidence of solid tumors was 7.3% at 10 years and 
increasing to 23.5% at 30 years, with breast cancer being the most common solid tumor. 
The most surprising finding was the incidence of a third cancer with the estimated 
cumulative incidence of 21% at 10 years after the second [10].  
 
Breast cancer is the most common cancer among women and is the second 
leading cause of death from cancer [1]. Women treated for HL with mediastinal radiation 
at 30 years of age or younger have the highest incidence of breast cancer, outside familial 
syndromes [11]. The risk is greatest at 15 to 20 years after initial HL diagnosis, which is 
more than 20 years before the median age (61years) of breast cancer among the general 
population [3, 7, 20]. The mechanism for secondary breast cancer following mediastinal 
radiation is not well established, but specific risk factors have been identified. Specific 
demographic and treatment characteristics identified as risk factors contributing to 
secondary breast cancer include: dose of mediastinal radiation, age at the time of HL 
diagnosis and therapy, endocrine function, and familial cancer history including inherent 
genetic variability [3-6, 8, 12, 13].  
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Researchers have developed predictive models of cumulative risk of breast cancer 
among women treated for HL [11] based on treatment, age at therapy and length of 
follow-up as well as family history. It could be argued that pediatric HL patients treated 
on identical treatment regimens are matched on the variables of treatment, age, and 
follow-up; therefore, all are seen as high risk for secondary breast cancer. Therefore, the 
genetic variability at the time of therapy may play the greatest role in determining those 
of increased sensitivity to the prescribed therapy, most specifically radiation. A recent 
study found an increased relative risk of breast cancer after HL with a positive first 
degree family history of cancer [43]. While the family history is a significant predictor of 
future health status, family history in the pediatric patient should also consider the health 
status of second degree relatives.  Many of the first degree relatives of pediatric HL 
patients may not have developed a cancer due to the background of time, while predictors 
may be with the secondary degree family members. For the pediatric HL survivor one 
should consider all the associated risk factors; radiation, chemotherapy regimens, age at 
therapy, and family history; however, there appears to be no straightforward predictor for 
the development of secondary breast cancer [44]. 
 
 
Demographic and Treatment Characteristics of the Primary Cancer 
 
 
Radiation 
 
The risk factor that is most strongly associated with the development of secondary 
breast cancer is mediastinal radiation including the radiation dose received as part of the 
treatment for HL. The radiation dose of ? 40 Gy has been associated with the highest risk 
of secondary cancer with a 23.3 fold increase in comparison to 20-39 Gy which is 
associated with a  5.9 fold increase [15]. While the lower dose of radiation is thought to 
reduce risk of secondary cancer, women who received radiation therapy alone at doses of 
4 Gy to the breast continued to have a 3.2 fold increase in development of breast cancer 
[13].  Another study found that the risk of secondary breast cancer was increased in HL 
patients compared to the general population regardless of the radiation dose [5]. Although 
current treatment protocols use combined modality therapy, the risk of lower dose 
radiation < 20 Gy has not been established. It is believed that the reduction in volume of 
exposed breast tissue and radiation dose reduction to 20-30 Gy will change the long-term 
risk profile of patients cured of HL [45]. While the association has been made with 
radiation and the occurrence of a secondary breast cancer, there is clearly no radiation 
dose that is without the risk of breast cancer. All pediatric HL survivors treated with chest 
radiation appear to be at an increased risk regardless of the radiation dose.  
 
 
Age at HL Diagnosis 
 
Along with radiation, age at the time of HL diagnosis has been implicated as a 
risk factor for secondary breast cancer. As stated earlier, the greatest risk of secondary 
breast cancer has been found in women treated for HL prior to the age of 30 years [7, 13]. 
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Women radiated prior to 30 years of age appear to have an excess risk 15-20 years after 
therapy and beyond 20 years, with a 2.3-3.7% excess risk per person per year [8].  
 
Young age at the time of radiation and the occurrence of breast cancer parallels 
the well established concept of increased sensitivity of young breast tissue to ionizing 
radiation [11]. An earlier age of risk has been proposed by Travis et al. [13] who 
determined the relative risk (RR = ratio observed/expected) of radiation associated breast 
cancer for subgroups defined by age and found the risk to be greatest in women who 
received radiation therapy at the time of puberty, 13-17 years. Another study explored the 
risk factor of age using the multiple Poisson regression of standard incidence ratios. The 
regression model analysis found the risk of secondary breast cancer to be greatest in girls 
treated for HD at 5-9 years of age [6].  To further explore the correlation of age at HL 
diagnosis and secondary breast cancer, another study used two statistical approaches, the 
Cox regression and Poisson regression of standard incidence ratio. Each method had 
similar results and the study concluded that there is little statistical evidence for an 
association between age at diagnosis of HL and the development of secondary breast 
cancer [46]. As noted, the studies that have examined the association of secondary breast 
cancer and age at HL treatment have found varying ages of association. It is known that 
women undergo an increase of breast tissue proliferation during the early menarche years 
and first pregnancy [47]. Therefore, an age of radiation therapy prior to 30 years is 
perhaps more inclusive of those at risk of secondary breast cancer and would include the 
ages of breast vulnerability.  While the relative risk of breast cancer is highest 15-20 
years after radiation therapy, this relative risk will decrease with time. However, due to 
the background risk of breast cancer with increasing age, HL survivors have a decreased 
relative risk and an increased absolute risk and cumulative incidence of breast cancer 
with age [7]. 
 
 
Endocrine Influences 
 
Ovalatory function and most specifically the greater number of lifetime ovulatory 
cycles has been well established as a risk factor associated with breast cancer. This 
lifetime exposure to sex hormones is determined by age at menarche, age at first full 
pregnancy, the number of pregnancies, and age at menopause. Early menarche is less 
than 12 years of age for initiation of menses and is thought to increase breast cancer risk 
secondary to prolonged breast exposure to estradiol during adolescence [48]. In relation, 
the delay of menopause maximized the number of ovalatory cycles and may therefore 
increase breast cancer risk. Many women with significant risk factors for breast cancer 
are advised to have ovariectomy prior to 45 years to induce menopause and thus 
decreasing breast cancer risk by 40% [49].  
 
  After radiation, the risk of secondary breast cancer increases if the women has a 
larger number of premenopausal years due to prolonged ovulation and hormonal 
influences [14]. Women treated for HL have been found to experience early menopause 
secondary to ovarian irradiation and alkylating chemotherapy which results in ovarian 
dysfunction, reduced hormonal influence, and a theorized reduction in breast cancer risk 
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[11, 13, 14]. Reaching menopause, as early as 31 years of age has been associated with 
the strongest reduction in breast cancer and remains beneficial if achieved by 36 years in 
comparison to those remaining premenopausal or entering menopause after 45 years of 
age [14]. Additionally, the relative risk is reduced if there are less than 15 years of 
ovulation after HL therapy [14]. After HL therapy, ovarian failure may occur at a 
radiation dose of 5 Gy or more to the ovaries, and ovarian failure is greatest when the HL 
treatment includes both pelvic radiation and alkylating agents [13, 14]. According to 
Travis et al. [11], women treated with radiation and alklyating agents had a 1.4 fold 
increased risk of secondary breast cancer in comparison to a 3.2 fold increase in women 
treated with radiation alone; therefore, the addition of alkylating agents further decreased 
the ovarian function and decreased the breast cancer risk. Other data suggest that young 
women treated with mediastinal radiation without alkylating agents have increased risk, 
comparable or slightly smaller than those with BRCA mutations who have a 65-80% risk 
[11].  Another study found a protective effect of pelvic radiation, but did not find a 
protective effect of alkylating agents even at higher doses [3]. Although the use of 
alkylating agents has been documented as being protective, the timing of the alkylating 
exposure may effect the chemotherapies induction of premature menopause [50]. 
Furthermore, Travis et al found the trend of protection was not statistically significant in 
HL patients when treated at 21 years of age or younger [13]. While several studies have 
cited the administration of alkylating agents and pelvic radiation to be breast cancer 
protective, pelvic radiation may be the most protective among pediatric HL patients. For 
the patient less than 21 years of age the administration of alkylating agents without pelvic 
radiation may offer little benefit of early menopause. To determine the effect of 
chemotherapy and pelvic radiation, dosing of alkylating agents and chemotherapy was 
determined for each case and control within the study.  
 
The use of exogenous hormones is strongly linked to an increased risk of breast 
cancer among postmenopausal women within the general population [51]. The link of 
exogenous hormones and breast cancer has also been made in women using oral 
contraceptives. A large meta analysis found that risk was strongest while taking oral 
contraceptive, with a persistent decreasing risk up to 10 years after hormone cessation. 
Additionally, this analysis found initiation of oral contraceptive prior to 20 years of age 
increases risk as opposed to initiation at an older age [52]. Studies have examined the 
association of hormone use after HL therapy and  have been unable to clarify the risk of 
early on-set breast cancer, hormone therapy and HL  [14, 53]. The question remains if use 
of hormone therapy diminishes the beneficial effect of premature menopause and should 
all HL survivors discontinue hormone therapy by 31 years of age, when menopause is 
most beneficial.  
 
In addition to chemotherapy and radiation, the endocrine function of ovulation is 
decreased with pregnancy and is associated with a decreased breast cancer risk, 
especially with early age at first pregnancy. A study of  Japanese bomb survivors found 
that the dose of radiation and nulliparity act multiplicatively in causing breast cancer with 
parous women giving birth at a younger age demonstrating lowest risk [54]. Although 
pregnancy decreases the number of ovalatory cycles and is protective, the exposure of 
pregnancy hormones on breast tissue results in an increased risk for primary and 
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secondary breast cancer 3 to 7 years after childbirth in women previously treated for HL 
[53]. Furthermore, Hill et al [53] found that women with a history of HL had an increased 
relative risk to other parous women if they delivered within 60 months after HL therapy. 
This risk is thought to be related to increased production of prolactin and lactation which 
promote mammary carcinogenesis after radiation. To determine the hormonal influence 
among the cases and controls, treatment variables of chemotherapy and radiation were 
collected, as well as age of menarche, menopause, history of pregnancy and use of 
hormonal therapy.  
 
 
Family History 
 
 Hodgkin lymphoma occurs within families, and siblings of HL patients have an 
increased risk of developing the same cancer [3]. The family history of women who 
developed a second cancer after HL has been reviewed to determine if the family history 
is significant for the development of secondary breast cancer. It has been hypothesized 
that HL survivors with a family history of breast cancer have a higher risk of developing 
secondary breast cancer and suggest the presence of cancer predisposing genetic risk 
factors. In a case-control study of HL survivors treated prior to 30 years, a positive family 
history of breast or ovarian cancer in a first or second degree family resulted in a 2.5 fold 
increased breast cancer risk [53]. Furthermore, it has been suggested that a family history 
of breast or ovarian cancer influences one’s response to radiation therapy leading to the 
development of breast cancer. Hill et al. [53] found that the combined effect of a breast or 
ovarian family history  and increasing radiation dose does not exceed that of women 
without this history and may be lower. These findings may be more relevant to the age of 
radiation exposure to the young breast than the cumulative factor of family history and 
radiation dose. There may also be ascertainment bias in obtaining the breast cancer 
history in HL survivors with secondary breast cancer in comparison to controls.  
 
In documentation of family history, several studies find that family cancer history 
is more significant [18, 43, 53] than breast cancer history alone.  A study by Nichols et al 
[18] identified a cohort of Hodgkin survivors and found 21% (11 of 52 patients) with a 
positive family history of cancer to have developed a secondary breast cancer. Family 
history in this study included the proband and two other relatives with cancer over 2 
generations in the paternal or maternal lineage. This cohort was compared to another 
cohort of Hodgkin survivors without a secondary cancer and found to have only 4% (3 of 
68 patients) with a positive family history of cancer. The study concluded that a subset of 
HL survivors with a positive cancer family history will have a higher incidence of 
secondary tumors than those without a cancer family history [18]. A more recent study 
examined the risk of a secondary cancer among lymphoma patients with a family history 
of cancer [43] and found an increased relative risk of breast cancer among HL survivors 
with  a positive family history of cancer. It was suggested that this family history presents 
risk associated with DNA disrepair, shared environment, or interaction. To determine the 
prevalence of breast cancer and familial cancers among the study cases and controls, a 
two generation family history of both maternal and paternal lineage was obtained.   
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Other Breast Cancer Risk Factors 
 
The consumption of alcohol has been associated with breast cancer risk in both 
pre- and postmenopausal women [55]. There are several mechanisms through which 
alcohol is thought to increase breast cancer risk. Alcohol may act through its first 
metabolite, acetaldehyde, leading to procarcinogen activation [56] or increase estrogen 
levels in both pre- and postmenopausal women [57, 58]. Alcohol also affects the 
synthesis of nutritional supplements including folate, pyridoxal phosphate (methyl group 
synthesis and transfer), vitamins B12, D, A, E, retinoids, zinc, and selenium. These 
nutritients are essential in amino acid metabolism and response to oxidative stress and 
DNA repair[59] which when depleted enhance carcinogenesis [56]. The use of alcohol 
was not collected on the cases and controls due to the concern for the lack of recall prior 
to the onset of breast cancer and ascertainment bias in the cases. Other contributing breast 
cancer risk factors include dietary fat, physical activity, body mass index (BMI).  
 
 
Characteristics of Secondary Breast Cancer 
 
Women at greatest risk for secondary breast cancer are those who receive 
treatment for HL prior to 30 years of age [7-9]. The onset of secondary breast cancer after 
radiation is 15-20 years, occurring 20 years prior to the median age of onset among the 
general population [3, 5, 7]. The characteristics of the disease and axillary nodal status 
are important in determining the long term prognosis. Women who develop secondary 
breast cancer may have histories of atypical breast hyperplasia or high mammographic 
density which confers a 3-5 fold excess risk of breast cancer [53] and a ninefold increase 
if the women also has a family history of breast cancer [49]. In addition, hormone therapy 
users within the general population are more than twice as likely to have high risk breast 
density on mammography in comparison to non-users [60]. Therefore, history of atypical 
breast disease or high mammographic breast density should indicate the need for diligent 
screening and counseling. In addition to these clinical findings, the breast cancer 
histological features, stage, and hormone receptors of HL survivors are similar to those in 
the general population [3]. Furthermore, these women commonly present with tumor of 
the medial breast and ductal carcinoma in situ. Lastly, secondary breast cancer presents 
as bilateral disease in 10-30% of the breast cancer cases, while bilateral presentation is 
only seen in 4-6% of the sporadic breast cancer cases [3].  
 
 
Candidate Germline Mutations 
 
Common germline mutations associated with familial breast cancer syndromes 
such as ATM, TP53, BRCA1 and BRCA2 became candidate genes for explanation and 
examination within the HL survivors with secondary breast cancer. One of the first 
germline mutations to be examined was the heterozygous inactivating mutation in ATM, 
the gene defective in ataxia-telangiectasia and associated with defective DNA repair 
mechanisms and the development of cancer. The study used a protein truncation assay 
with 52 patients who had a second cancer after treatment for HL. Mutation of the ATM 
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gene was not found to occur in excess frequency among these survivors with second 
cancers [18]. Variants within the ATM gene have also been considered. Thirty-seven 
women with breast cancer after HL disease were matched for age at diagnosis and year of 
diagnosis with 27 women after HL without breast cancer; heterozygous protein-
truncating or missense mutations of ATM were again not associated with second cancers 
[61].  
 
Mutations in the familial tumor suppressor genes, TP53, BRCA1, and BRCA2 
have also been explored [19]. Analysis of Hodgkin survivors with secondary cancers 
including breast have been conducted. Mutational analysis using genomic DNA was 
completed on 44 patients for the presence of the TP53 germline mutation. Nineteen of the 
survivors with secondary breast cancer were also surveyed for presence of the BRCA1 
and BRCA2 germline mutations. Importantly, the study was unable to locate germline 
mutations that have been associated with the development of cancer, specifically TP53, 
BRCA1, or BRCA2 [19]. To further examine a possible mutation of the BRCA1 and 
BRCA2, loss of herterozygosity of these genes was evaluated but was not found [62]. 
This has led researchers to speculate that second cancers among HL survivors is a result 
of inactivating germline mutations in other DNA repair genes not yet identified that 
interact with TP53, BRCA1, and BRCA2 [18, 62].  
 
 
Candidate Polymorphisms 
 
Because the surveillance of leading candidate genes has not provided insight into 
the etiology of secondary cancers, the focus has shifted to candidate polymorphisms. The 
study of common population polymorphisms of drug metabolizing enzymes has become 
an area of interest, most specifically those of the glutathione-S-transferase (GST) [20, 21, 
63]. It is hypothesized that a homozygous genetic deletion of the null genotype of (GST) 
M1 and P1 may impair the detoxification of environmental genotoxins or chemotherapy 
resulting in a secondary malignancy [21]. The Childhood Cancer Survivor Study (CCSS), 
a multi-institutional study group conducted a longitudinal study on 14, 054 survivors of 
childhood cancer and explored the possibility of gene polymorphisms within the GST and 
XRCC1, a key member of the base excision repair, as contributing to second cancers 
among HL survivors [7]. From this data base, 650 Hodgkin survivors submitted buccal 
cell specimen for GST study. The results suggested a modest possible role of the GSTM1 
null genotype, loss of function, in the development of secondary cancers; however, the 
effect was only significant when the GSTM1 and GSTT1 were considered together [7]. 
The study also examined the polymorphism of XRCC1 which participates in DNA strand 
break repair and is important in radiation therapy recovery. The results were not 
statistically significant but suggested that the presence of 1 codon 399 glutamine allele 
provided protection against thyroid carcinoma and a slight increase in secondary breast 
cancer. The CCSS research suggests that individual sensitivity may be a result of multiple 
gene interactions or complexes [7].  
 
Research supports that highly penetrant mutations such as BRCA1 and BRCA2 
are associated with only 5% of primary breast cancer occurrences [64]. Therefore, 
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investigators have hypothesized that the expression of less penetrant functional 
polymorphisms combined with environmental interactions are associated with the 
majority of disease. While candidate polymorphisms have been evaluated according to 
their biochemical and physiological pathways, there appears to be multiple gene 
interactions that may play a role in breast cancer onset. A recent study explored the 
association of primary breast cancer with individual genes and with two- and three- gene 
combinations. The study enrolled 1,716 women with primary breast cancer and 4,435 
controls to explore single gene polymorphisms in genes known to be associated with 
breast cancer. The findings were significant for two-and three-gene combinations 
suggesting an interaction of genes and the development of breast cancer [64]. While this 
study was conducted with primary breast cancer patients, it suggested the need for an 
exploratory study of gene expression and associated polymorphisms in determining gene 
to gene interaction. This is the approach of this study of women after secondary breast 
cancer.  While the etiology of secondary breast cancer among HL survivors is not the 
result of a single variable, the cited literature describes both primary and secondary breast 
cancer as resulting from multiple events or interactions. Thus far, the candidate genes and 
polymorphisms can not fully explain the multiple event or interaction. The hypothesis 
guiding this study was intended to could give additional insight into the interaction 
between treatment variables and inherent characteristics, genetic polymorphisms, of the 
individual and the role in development of secondary breast cancer.  
 
 
Testing Methodologies 
 
From the reviewed literature, determining the etiology of secondary breast cancer 
using a candidate gene approach has not been successful [18, 19, 61, 62]. Additionally, 
studies have found only weakly associated polymorphisms with an underlying etiology 
that is polygenic [20, 21, 63, 64]. The candidate gene and polymorphism approach has 
given limited information into the inherent predispositions; therefore, it is reasonable to 
undertake an exploratory study to describe and compare the whole genome expression 
and genotype of HL survivors with secondary breast cancer compared to those without 
secondary breast cancer. A case-control design was used in the current study and is one 
of two basic experimental designs used with gene-association studies [65]. This design is 
an emerging methodology to examine gene-environment interactions in populations with 
small sample sizes. The difference in global gene expression between groups was 
measured with the Affymetrix GeneChip® Human Genome U133 Plus 2.0 Array. The 
difference in genotype between groups was measured by the presence of single 
nucleotide polymorphisms (SNP), between groups with the Affymetrix GeneChip® 
Human Mapping 500K Set. Combined these analyses were compared to determine the 
significant global gene expression and genotype differences between the two groups. 
After determining significant differences between the case and controls, the genotype and 
global gene expression of only the women with secondary breast cancer were examined 
to determine candidate genes associated with genotype allele frequency.  
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Microarray Technology 
 
The technology of microarray analysis has exploded over the last 10 years, with 
this research technique being applied to numerous studies of medical and clinical 
relevance [66]. High-throughput microarray technology provides major areas of genomic 
exploration: genome-wide analysis of gene expression, SNP genotyping, copy number 
variants, transcript mapping, and resequencing [67]. This technique can now genotype 
drug metabolizing enzyme genes, resequence tumor suppressor genes, and classify cancer 
by differential gene expression and prognostic indicators. A number of studies have 
identified prognostic and predictive ‘gene’ signatures as prognostic indicators in the 
treatment of breast cancer [24]. Most of the early work with microarray analysis and 
primary breast cancer has been done with tumor samples taken at the time of surgery. 
These analyses have enabled researchers to analyze breast tissue and obtain a better 
understanding of the molecular characteristics and clinical behavior of breast cancer. This 
has been most helpful in the analysis of gene amplification and coamplification in 
prognosis and treatment of breast cancer [25] . Examination of breast tissue will give 
expression at the site of the disease, but will not give a global picture of the gene 
interaction that may have predisposed individuals to multiple cancers. With the 
hypothesis that the second cancer is the result of an inherent gene-gene/environment 
interaction, peripheral blood was the sample used for the global gene expression and 
genotype. 
 
The Affymetrix GeneChip® Human Genome U133 Plus 2.0 Array used in this 
study analyzes the expression level of over 47,400 transcripts and variants including 
38,500 human genes. The array is comprised of over 54,000 probe sets and 1,300,000 
distinct oligonucleotide features [29].  Microarray analysis allows genomic measurement 
of an individual’s gene expression under a variety of genetic and environmental 
conditions and may best capture biological phenomena through the interaction of 
multiple genes. This gene expression is typically measured as an up or down regulation 
of genes/gene pathways associated with the studied phenotype. This analysis has been 
used to study and compare healthy and diseased samples, using the steady state mRNA to 
infer maladaptive changes associated with disease. The earliest method was fold-change 
which is a metric for comparing a gene’s mRNA expression between two experimental 
conditions such as case-control. The challenge with fold change has been generalizability 
of findings with arithmetic definitions differing between investigators. While these 
studies have made it possible to compare the expression levels for active genes, 
challenges remain most specifically with study design, inference, gene classification, and 
validation [68].  
 
Single nucleotide polymorphism (SNP) analysis was performed using the 
Affymetrix GeneChip Human Mapping 500K set. This assay comprises two arrays 
designed for high throughput parallel genotyping of ~500,000 SNPs that span the human 
genome with a median intermarker distance of 2.5 kb [29]. The sequence of each allele is 
determined using 24 probes that interrogate the forward and reverse strands at six 
positions across each SNP. Genotype calls generated from the 500K Mapping assay 
(500k_datasheet.pdf) [29] are highly concordant (HapMap agreement, 99.3%) and 
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consistent (Mendelian consistency, 99.9%). Overall, 85% of the genome is represented 
within 10 kb of a SNP. Further, with a mean allele heterozygosity of 0.30 across a wide 
range of populations and ethnicities, the Mapping 500K set is well-suited for genotype 
analysis within diverse ethnic groups.  
 
The global gene expression from the Affymetrix GeneChip® Human Genome 
U133 Plus 2.0 Array was combined with the SNP genotype from the Affymetrix 
GeneChip Human Mapping 500K set in an association analysis. The SNP array data also 
anlyzed for amplification, deletion, or no change in copy number. The  expression data 
were treated as quantitative phenotype and the analysis screened the in silico copy 
number of the most significant SNP’s and found an association with the expression of a 
list of genes and pathways. An understanding of the gene expression may bring an 
understanding to the pathways that connect the genotype to the cellular traits [69] and a 
better understanding of the biological processes driving the association between 
expression and response. 
      
 
Summary of Review 
 
 The reviews of literature describe known risk factors associated with secondary 
breast cancer among HL survivors and include radiation, chemotherapy, age, time from 
diagnosis, hormonal influence and family history. While the radiation dose has been 
implicated as a significant risk factor, the risk is inclusive of all who are treated with 
chest radiation exposure regardless of treatment dose. The age of radiation exposure 
before 30 years has clearly been established as a risk factor, which would include all 
pediatric female HL survivors. Additionally, the time from exposure has been cited as 
being greatest at 15-20 years post therapy; however, these women continue to have an 
increased absolute and lifetime risk. Administration of alkylating agents has been 
associated with a decreased breast cancer risk; however, the timing of alkylating 
exposure in the pediatric population may not be protective. Perhaps pelvic radiation is the 
most productive endocrine insult, leaving the question and unclear association of 
hormonal supplementation in HL survivors. The hormonal influence of pregnancy within 
60 months after HL therapy has been found to be associated with an increased breast 
cancer risk and should be discussed with survivors. Lastly, the family history of not only 
breast cancer, but familial cancer should be reviewed with all HL survivors. The review 
of risk factors attempt to assist the clinician in identification of survivors at greatest risk 
for secondary breast cancer. However, it is my assumption that the pediatric HL patient is 
a vulnerable host due to radiation exposure of growing, immature cells and all are at an 
increased risk of secondary cancers. Therefore, this study was directed at exploration of 
inherent factors that impede the DNA repair, facilitate hormonal exposure, or prevent 
apoptosis leading to the development of secondary breast cancer. 
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CHAPTER 3. METHODS 
 
 
Research Design 
 
 
Research Design and Study Population 
 
This descriptive cross-sectional case-control study assessed the gene expression 
and genotype profile of women who are survivors of childhood HL (see Figure 3.1). The 
first group (cases) included women who were treated with mediastinal radiation and 
developed secondary breast cancer. The second group (controls) included women who 
were treated with mediastinal radiation and have not developed secondary breast cancer.  
 
The study definition of breast cancer was the development of documented breast 
cancer after treatment for pediatric HL, which included mediastinal radiation. Estimates 
regarding the timing of the second cancer range from 15-20 years after radiation exposure 
[1-2], The study definition for non-breast cancer was the absence of breast cancer and a 
negative mammogram within one year of study.  
 
 
Eligibility Criteria for Case and Control Participants 
 
• Females treated for pediatric HL at St. Jude Children’s Research Hospital 
between 1970 to 1991 
• 18 to 55 years of age 
• Cases had documented breast cancer prior to 51 years of age 
• Controls had documented negative mammogram within one year of participating 
in the study 
• Controls matched treatment variables of the breast cancer case and           
included: age at diagnosis, mantle/mediastinal radiation dose, para-aortic/splenic 
radiation dose, alkylating agents dose (cyclophosphamide and procarbazine), and 
time since diagnosis of HL 
• English-Speaking 
• Written consent for participation 
 
 
Exclusion Criteria  
 
• Confirmed diagnosis in the control group of any secondary cancer  
• Treatment within the last 6 months for any cancer, excluding basal and/or 
squamous cell carcinoma, in the case group 
• Inability or unwillingness of research participants or legal guardian/representative 
to give written informed consent 
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Hodgkin Lymphoma Treated with Radiation Therapy 
 
 
 
 
Development of Breast                                     Non-Development of  Breast 
       Cancer (Case)  n=13                                             Cancer (Control)  n=36 
 
Figure 3.1 Study Design. 
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Procedures for Accomplishment of Aims 
 
 
Case and Control Participation    
 
The case/controls were taken from the data base of active alumni who were 
treated for pediatric HL at St. Jude Children’s Research Hospital (SJCRH) between July 
1970 and July 1991. After obtaining Institutional Review Board approval  (XPD05-108), 
a retrospective chart review was conducted and found 440 persons treated for pediatric 
HL within these years, of which 190 are women and 19 (10%) of these women 
subsequently developed secondary breast cancer. Of the 19 women with secondary breast 
cancer, 13 women were identified as survivors of secondary breast cancer after HL.  All 
surviving secondary breast cancer patients (cases) were asked to participate in the study, 
while the control participants were selected based on controlling variables from the 
treatment characteristics. Once the cases were identified, the protocol was submitted for 
approval from the SJCRH and University of Tennessee Institutional Review Board 
(Appendix A). 
 
The 13 HL breast cancer survivors are the study cases and were matched with 3 
controls, based on power estimates as discussed in the statistical section. In identifying 
the controls, 101 women were eligible as controls and were randomly selected by the 
study biostatistician after matching on the variables of age at diagnosis, 
mantle/mediastinal para-aortic and pelvic radiation dose, alkylating agent 
(cyclophosphamide and procarbazine) dose, and time since HL diagnosis. These variables 
were classified into classes based on Low/None, Medium and High groups. This led to no 
match for four cases. Since the list of the controls was limited in matching with all cases, 
the median cut-off for age at diagnosis and time since diagnosis was used. The final age 
classes were age < 14.7608 years (Age Dx Class =1) and age >= 14.7606 (Age Dx Class 
=2) and time since diagnosis < 27.8696 years (Time Dx Class =1) and time since 
diagnosis >=27.8696 (Time Dx Class=2).  The dose of maximum chemotherapy was then 
calculated ‘Max Chemo’ dose based on the maximum doses of Cyclophosphamide and/or 
Procarbazine patient received. This chemotherapy dose was defined as high and low dose 
of Max Chemo dose using a cut-off <7000 mg (Max Chemo Class =1) and >= 7000 mg 
(Max Chemo Class=2). Similarly, the dose of radiation was calculated using the same 
analogy as for Max Chemo class to define Max Radiation Class, where Max Radiation 
Class =1 when Max Radiation < 30 Gy and Max Radiation Class=2 when Max 
Irradiation >=30 Gy and Max Irradiation is the maximum amount of radiation patient 
received at Mantle, Mediastinum, Paraarortic and/or Pelvic. When more than 3 possible 
controls were available for each case, simple random sample was used to select controls. 
The controls were matched on variable significance with the most important being 
radiation dose, then chemotherapy, time since diagnosis, and age at diagnosis 
Of the 13 cases, one was treated on HOD 68, four cases were treated on HOD 72, five on 
HOD 80, one on HOD 90 and two according to best clinical management.  Eight of the 
cases received alkylating agents, while four were treated with radiation alone. The dose 
of mantle/mediastinal radiation ranged from 39-20Gy. The controls were treated with 
similar doses of chemotherapy and radiation according to their matched case.  If a control 
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was not located or unable to participate, the biostatistician continued the randomization 
of controls, this process was repeated as needed until all matched controls were 
considered. If a control was found to be a case, the control was reclassified as a case and 
matched with 3 controls.   
 
Once the cases and controls were identified, eligible participants were discussed 
with the SJCRH alumni physician. An introductory letter (Appendix B) and consent form 
(Appendix C) was mailed to the eligible participants explaining the purpose of the study 
and requirements of obtaining demographic information (Appendix D)  and a blood 
sample. Two weeks after receiving the letter, each eligible participant received a follow-
up phone call from the primary investigator (PI), who responded to questions and 
obtained verbal consent for completion of a demographic health questionnaire over the 
phone. After the participant gave verbal consent for the study, the demographic questions 
were reviewed and responses from each participant recorded by the PI for validation 
accuracy. The demographic responses were recorded and categorized; accuracy of 
extraction and categorization were verified for inter-rater reliability with another 
researcher with 98% agreement between raters. Written consent was obtained from all 
participants and returned to SJCRH.  Once this consent was received, each participant 
was officially entered on study and mailed a kit for blood collection. To enhance the 
scope of future research of HL and secondary cancers, a biological repository consisting 
of stored blood (DNA, serum phase) from all participants was discussed with each 
participant and written consent was obtained for those agreeing to participate in the 
biological repository.  The stored DNA sample was obtained from the initial 7mLs of 
blood collected in the EDTA tube.   
 
 
Enrollment of Cases and Controls 
 
Ten of the 13 known survivors of secondary breast cancer were initially enrolled 
on study. Three of the survivors were lost to follow-up; however, it was later learned that 
one of these lost to follow-up had died within the previous two months secondary to 
bacterial colitis. The matched controls to these 10 cases were then contacted for 
enrollment. Telephone contact with these controls found two additional Hodgkin 
survivors with secondary breast cancer. One had developed breast cancer within the 
previous 6 months, while the other had been diagnosed within the month and had 
received no breast cancer therapy. These women were then enrolled as cases and 3 
controls were matched for each. A study packet was sent to all potential controls with 
follow-up telephone contact. The number of participants who gave consent, were 
ineligible, declined, or who were lost to follow-up from the initial case control matched 
variable randomization are included in Table 3.1.  
 
Fifty one controls were contacted, with 34 found to be eligible and consenting to 
participate. Two agreed to participate, but were ineligible due to a secondary basal cell 
carcinoma and another due to pregnancy secondary to gene expression associated with 
pregnancy. Another who was consented and enrolled on study was not included in the  
demographic analysis due to subsequent development of hepatocellular carcinoma but 
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Table 3.1 Initial Control Contact for 12 Matched Cases. 
 
Control Participation Responses 
Controls contacted via mail or phone n=51 
Consented n=34 
Ineligible at time of contact n=2 
Declined n=3 
Lost to follow-up n=12 
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was included in the expression and genotype analysis. Three declined participation due to  
time conflict in arranging blood collection and 12 were lost to follow-up. A total of 34 
controls were enrolled from the initial case-control matching, with 33 meeting all 
eligibility criteria. The list of potential controls was reviewed for additional participants 
on the criteria of radiation dose and chemotherapy as previously described. Three 
additional controls were identified and matched as described, with one consenting (35 
controls) to study and two lost to follow-up. No other controls were matched to the cases 
on the variables of radiation and chemotherapy dose.     
 
Approximately 6 months after the study began, the 13
th
 case was reported to the 
SJCRH database and this survivor was subsequently enrolled. In matching on race 
(African American) and disease variables, only three controls were identified with one 
consenting and two lost to follow-up. This resulted in 13 cases and 36 controls. Ten cases 
have 3 matched controls per case, 2 cases have 2 matched controls per case, and the last 
case described had only 1 matched control.     
 
 
Blood Collection for RNA and DNA Extraction 
 
Sample collection was discussed with each participant and arrangements were 
made accordingly. The samples were collected at SJCRH, an affiliate clinic, local 
physician’s office, or at the participant’s residence. Samples were collected by a 
registered nurse, technician, or physician designee. Collection supplies and instructions 
were provided to those responsible for blood collection. Instructions regarding overnight 
mailing and shipping procedure were also outlined. No cost to the participant was 
associated with the blood collection. Risks associated with the venipuncture were shared 
with participants and included the possibility of bruising at the venipuncture site.  
 
      For RNA extraction, 5 milliliters (mL) of blood were collected directly into two 
2.5mL PAXgene™ Blood RNA System (Qiagen, Valencia, CA). The PAXgene tube 
contains a reagent that stabilizes intracellular RNA by reducing RNA degradation. The 
blood was collected into the PAXgene tube according to manufacture’s instruction. After 
collection, each tube was inverted 10 times and stored in an upright position for a 
minimum of two hours at room temperature to allow for incubation. At the completion of 
incubation, samples were stored on ice for shipment to SJCRH. The samples were stored 
at -20ºc for a minimum of 24 hours and then transferred to a non-frost free freezing unit 
an stored at -80ºc until processing.  
 
For DNA extraction, 7 mLs of whole blood was collected in tubes containing 
EDTA as an anticoagulant. The blood sample was mixed and placed on ice for shipment 
to SJCRH. If the sample was not immediately processed, the sample was stored at 4º for 
up to 72 hours.  
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RNA Extraction 
 
The RNA extraction was performed under the Processing Clinical Samples for 
DNA, RNA, Protein and Cryopreservation Procedures Manual within the Department of 
Pharmaceutical Sciences at SJCRH. Samples collected for RNA extraction were removed 
from the -80ºc freeze and placed in a 37ºc water bath for a quick thaw. In the lab, the 
RNA was extracted using the TRI REAGENT® protocol. After thawing, the tubes were 
centrifuged for 10 minutes at 5000xg (gravitational acceleration) using a swing-out rotor 
at room temperature. After centrifuge, the supernatant was decanted and discarded. Five 
mL. of RNase-free water was added to the pellet. The pellet was resuspended into 
solution and transferred to an 8cc polypropylene tube and capped. The tube was 
centrifuged for 10 minutes at 5000xg in a swing-out rotor at room temperature.  After 
centrifuge the supernatant was removed. Two mL of TRI reagent was added and mixed 
well with the pellet. The TRI reagent was allowed to digest for 5 minutes. The 
homogenate was then supplemented with 0.4 mL chloroform (0.2 mL for 1mL of TRI 
reagent) and vortexed for 15 seconds. The mixture was stored at room temperature for 5 
minutes and then centrifuged at 12000 rcf for 15 minutes at 4ºc. A sterile transfer pipette 
was used to transfer the colorless upper aqueous phase into a new tube. To the colorless 
aqueous fluid, 1 mL of isopropanol (0.5 mL of isopropanol per 1 mL of TRI reagent used 
in the initial homogenization) was added. The mixture was vortexed and stored at room 
temperature for 5 minutes. The mixture was then centrifuged at 12000 rcf for 15 minutes 
at 4ºc. The supernatant was discarded and the tube dried without disruption of the RNA 
pellet. One mL of cold 75% ethanol was mixed with the pellet into solution and 
transferred into a 1.5 mL microtube (Axygen). The pellet/ethanol mixture was 
centrifuged at 10000 rcf for 5 minutes at 4ºc. The supernatant was discarded, leaving the 
RNA pellet to which 10-15 mcl of RNase free water was added. The pellet and water 
were mixed with 11 mcl of solution placed in a 0.5 mL microtube (Axygen). Both 
microtubes were placed on ice, with the 0.5 mL microtube transported to the Hartwell 
Center for processing. The remaining RNA solution was placed in an 80ºc non-frost free 
freezer for disposal at the completion of the study.  This system typically yields 4-10?g 
of pure RNA from 2.5 mLs of blood.  
 
 
DNA Extraction 
 
  All buffers and reagents used in the extraction process were commercially 
purchased in the QIAGEN Blood and Cell Culture DNA Kit. The 7 mL. blood samples 
were transferred from storage and each was transferred to a 50 mL screw-cap labeled 
tube. The lysis protocol began with 1 volume (7mLs.) of ice-cold Buffer C1 and 3 
volumes (21mLs.) of ice-cold distilled water. The tubes were then inverted several times 
and incubated in an ice bucket for 10 minutes. The Buffer C1 lyses the cells but stabilizes 
and preserves the lymphocyte nuclei. The blood suspension becomes translucent due to 
lysing of the erythrocytes and release of hemoglobin.  
 
After ice incubation, the 50mL tube of lysed blood was centrifuged at 4ºC for 15 
minutes at 1300xg. The blood suspension was poured off and the nuclear pellet was 
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visible. Ten mLs of Buffer G2 was added into the tube and the tube was vortexed for 30 
seconds at maximum speed, resuspending the nuclei. The resuspended nuclei was then 
mixed with 200?l of QIAGEN Protease and incubated in a 50ºC water bath for 60 
minutes. The Buffer G2 and QIAGEN Protease work together in striping the genomic 
DNA of all bound proteins, facilitating efficient DNA removal during purification.  
 
Part II of the DNA extraction process was isolation of genomic DNA from the 
nuclei. Prior to beginning this process, QIAGEN Genomic-tip 500/G was equilibrated 
with 10 mLs of Buffer QBT and allowed to empty by gravity flow. Once the equilibration 
buffer emptied from the genomic-tip, the sample was removed from the water bath and 
vortexed for 10 seconds at maximum speed. This step prevents poor DNA flow rates due 
to increased viscosity. The DNA was then filtered through the equilibrated genomic-tip. 
Once the DNA completed gravity flow through the genomic-tip, 2 x 15 mL washings of 
Buffer QC were filtered through the tip. These two washings are sufficient to remove all 
contaminants in the majority of DNA preparations.  
 
The QIAGEN Genomic-tip was then placed over a clean 30 mL collection tube 
and the genomic DNA was eluted with a 15 mL washing of prewarmed Buffer QF. The 
warming of the buffer increases DNA yield. To precipitate the DNA,10.5 mLs. of 
isopropanol was added to the eluted DNA and centrifuged at >5000xg for 15 minutes at 
4ºC.  
 
Lastly, the DNA pellet was washed with 1 mL. of 70% ethanol, vortexed, and 
centrifuged at >5000xg for 15 minutes at 4ºC. The supernatant was removed and the 
DNA pellet was allowed to air dry in the tube for 5-10 minutes. The DNA was 
resuspended in 1 mL of TRIS(TE) EDTA Buffer, ph 8.0. DNA dissolves best under 
slightly alkaline conditions with a ph 8.0-8.5. To facilitate the concentration 
equilibration, the suspension was transferred to a microcentrifuge tube and placed on a 
rotator (Labnet labroller) overnight.  
 
After the DNA samples were rotated overnight, the concentration of each was 
determined with the technique of PicoGreen® ultrasensitive fluorescent nucleic acid stain 
use for quantization of double-stranded DNA (dsDNA) in solution protocol. After the 
DNA concentration for each sample was determined, 50 nanograms (ng) of each sample 
were run on an electophoresis gel at a concentration of 0.8% with High DNA Mass ™ 
Ladder by Invitrogen. High DNA Mass™ Ladder is suitable for estimating the mass 
(quantity) of unknown DNA samples by ethidium bromide staining. This ladder consists 
of an equimolar mixture of six blunt-ended DNA fragments of 10, 6, 4, 3, 2, and 1 kb. 
Electrophoresis of 4 ?l of the High DNA Mass™  Ladder results in bands containing 200, 
120, 80, 60, 40, and 20 ng (520 ng total) of DNA, respectively. The gels were run at 75 
volts for 180 minutes. At the completion, each gel was removed and placed in the 
Fotodyne transilluminator and camera and analyzed with the Fotodyne Electrophoresis 
Gel Analysis Software. This software program provides quantification of the sample 
through the use of the High DNA Mass™ Ladder and provides an accurate molecular 
weight and DNA quantity calibration. After each sample concentration was determined, 
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250ng of DNA was plated into a 96 well plate for Nsp analysis and 250ng of DNA was 
plated into a 96 well plate for Sty analysis and forwarded to the Hartwell Center.  
 
 
Measurement of RNA: Quality Control 
 
The purity and quantity of RNA was measured using a Spectromax Plus 384 
spectrophotometer. The OD260 values were used to quantify the concentration, while the 
OD260/280 ratios were used to assess the purity of the RNA sample. OD260/280 ratios 
between 1.9 and 2.1 indicate high purity of RNA; ratios <1.8 were associated with 
protein contamination, while ratios >2.1 indicated carryover of small oligonucleotides 
and nucleotides. RNA quality was also evaluated with an Agilent 2100 Bioanalyzer. An 
electrophoresis profile generated by an Agilent analysis was used to calculate the relative 
abundance of the 28S and18S ribosomal RNAs which are surrogate markers of mRNA 
degradation. A ratio <2.0 indicated RNA degradation which can also be seen as 
fragments running ahead of the 18S species. RNA samples that passed these quality 
control measures were processed for Affymetrix GeneChip analysis. Five samples did not 
pass these quality control measures and the additional PAXgene tube was extracted for 
RNA and resubmission to the Hartwell Center for quality control and processing. All five 
passed quality control upon the second process.  
 
 
Processing of Extracted RNA: Hartwell Center, SJCRH 
 
As discussed, gene expression analysis was performed using the Affymetrix HG-
U133Plus2 GeneChip array. RNA samples were processed using the Affymetrix 
Eukaryote Two-Cycle Target Assay (www.affymetrix.com/support/technical). In the 
process, 100 ng of total RNA was used as starting template for cDNA synthesis. The 
RNA was annealed to a T7-oligodT(24) primer containing the recognition site for the 
bacteriophage T7 RNA polymerase. A first cycle of cDNA synthesis was accomplished 
using the SuperScript II cDNA synthesis kit according to the manufacturer’s conditions 
(Invitrogen). The resulting cDNA was then used as template for generating antisense 
cRNA using the MEGAscript T7 in vitro transcription kit (Ambion). The purified cRNA 
(400 ng) was then primed with random hexamers to initiate a second cycle of cDNA 
synthesis. The second round cDNA was then used as a template to generate biotin-labeled 
cRNA using the Affymetrix GeneChip In Vitro Transcription labeling kit. Twenty 
micrograms of biotin-labeled cRNA was fragmented by heating and metal induced 
hydrolysis and added to a hybridization cocktail containing probe array controls and 
blocking agents (BSA and herring sperm DNA),then incubated overnight at 45° C on a 
GeneChip array. Following hybridization, the arrays were washed automatically using a 
GeneChip Fluidics Station 400 under high stringency conditions to remove non-
hybridized labeled cRNA. To detect bound target, arrays were stained with Streptavidin 
Phycoerythrin (SAPE, Molecular Probes), washed again, and then scanned using the 
Affymetrix GeneChip Scanner 3000.  
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Expression signals for each transcript were calculated by the MAS5 statistical 
algorithm using the Affymetrix GCOS software (version 1.4). In this method, the global 
signals on the array were scaled to a 2% trimmed mean of 500. Detection calls (Present, 
Absent or Marginal) were determined using the default parameters of the software and 
recommended by the Affymetrix GeneChip protocol.   
 
 
Processing of Extracted DNA : Hartwell Center, SJCRH 
 
DNA samples submitted for SNP analysis were processed according th the 
Affymetrix protocol (affymetrix/500k_assay_manual.pdf). Total genomic DNA (250 ng) 
was digested with a restriction enzyme (10 units of NspI or StyI, 2h at 37 C), and then 
ligated to adapters that recognized the cohesive four bp overhangs (800 units T4 DNA 
ligase, 0.75 uM adapter, for 3 hours at 16°C). Each adapter contained a unique sequence 
that permited amplification by using a single PCR primer. The ligated DNA was 
amplified using thermocycling conditions (5 uM primer, 1X Clontech TITANIUM Taq 
polymerase; 30 cycles of 30 sec at 94°C, 30 sec at 60°C, 15 sec at 68°C) that enriched 
restriction fragments from 250bp to 1100 bp in size. This selective reduction in genomic 
complexity is key to the success of the mapping array. Following PCR, 90 ug of 
amplified DNA was fragmented to 25-100 bp by digestion with DNase I (0.25 units 
enzyme, 35 min at 37°C), end-labeled with 857 uM biotinylated-nucleotide using 
terminal deoxynucleotidyl transferase (105 units enzyme, 4 hours at 37°C), was added to 
a hybridization cocktail containing probe array controls and blocking agents (human Cot-
1 and herring sperm DNA). This mixture was then incubated overnight at 48°C on a  
GeneChip array. After hybridization, arrays were washed automatically using a 
GeneChip Fluidics Station 400 under high stringency conditions to remove non-
hybridized labeled DNA. Arrays were incubated with Streptavidin Phycoerythrin (SAPE, 
Molecular Probes), washed, and then incubated with biotin-conjugated anti-streptavidin 
antibody. After removal of the antibody solution, the arrays were re-stained using the 
SAPE, washed again, and then scanned using an Affymetrix GeneChip Scanner 3000. 
 
Genotype calls are initially determined using the Affymetrix Genotyping 
Software (GTYPE) version 4.0. The GTYPE software uses a dynamic model algorithm to 
call genotypes on an array by array basis. After processing the complete set of samples, 
genotype calls were generated using the BRLMM algorithm (also available within the 
GTYPE software). The BRLMM method [70] uses a multi-chip analysis algorithm which 
provides superior accuracy and consistency of calls as compared to the GTYPE 
algorithm.  
 
 
Statistical Procedures 
 
The study is based on a case-control design. The cases include 13 survivors and 
for each case there are three matched controls. This 1:3 matched case control design 
gives an efficiency of 75% for binary measures [71], an increase of 25% from a 1:1 
match. Controls were matched to cases based on the previously described variables 
including; mantle/mediastinal radiation dose, para-aortic/splenic radiation dose, 
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alkylating agent dose (cyclophosphamide and/or procarbaine), age at initial diagnosis, 
and time since HL diagnosis. In the surviving patients, 101 controls were identified and 
stratified based on the matching characteristics from which 3 controls from each stratum 
were randomly selected. If a control declined participation another control was randomly 
selected from the stratum of matched controls.  During the study if a control became a 
case, three matched controls (one for the original case and two for the new case) were 
randomly selected. It was proposed the study would take approximately 18 months. All 
data were collected and ready for analysis approximately 13 months after opening the 
study.  
 
Statistical analyses for specific aims are outlined as follows: 
 
 
Primary Aim One 
 
 Assess whether global gene expression profiles differ between two groups of 
radiated pediatric female Hodgkin lymphoma survivors with and without the 
development of secondary breast cancer.  
 
 Affymetrix U133 Plus 2.0 arrays were utilized to measure extracted RNA gene 
expression in blood samples taken from both the cases and controls.  Normalized gene 
expression signals were computed using Affymetrix MAS 5.0 software. The normalized 
signals were log-transformed prior to subsequent statistical analysis [72]. For each probe 
set, the two-sided Wilcoxon rank sum tests were used to compare the mean/median 
expression of the cases to that of the controls. To account for multiple testing, the set of 
resulting p-values was used to estimate the false discovery rate (FDR) with a robust 
method [73].   
  
 Gene-set enrichment analysis was performed with a structured permutation 
approach [74]. Affymetrix-defined pathways were used to define gene sets and the 
negative sum of Wilcoxon p-values was used as the gene-set statistic. The significance of 
the gene set statistic was determined via 10,000 permutations.   
 
 
Primary Aim Two 
 
 Assess whether genotype profiles differ between two groups of radiated 
pediatric female Hodgkin lymphoma survivors with and without the development of 
secondary breast cancer.   
 
 Affymetrix GeneChip® Human Mapping 500K Set was used to characterize the 
genotype of each case and control. The BRLMM algorithm [70], as implemented in 
Affymetrix software, was used to generate a genotype call (AA, AB, BB, or NoCall) for 
each of the 500K SNP markers and each sample.   
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 First, markers with low genotypic variability were removed due to statistical 
futility prior to subsequent analysis. For each of the remaining SNPs, the association of 
genotype with case-control status was explored with a chi-square test. To adjust for 
multiple-testing, the resulting p-values were used to estimate the FDR with a robust 
method [73] .  
 
      Additionally, the data were used to test for association of full-gene genotypes 
with case-control status using a structured permutation approach [74]. SNPs were 
mapped to genes on the basis of physical location relative to the start- and stop-
transcription positions. SNPs between the start- and stop-transcription positions or within 
5,000 base pairs of the start- and stop-transcription positions were mapped to the genes. 
The negative sum of log-p-values from the asymptotic chi-square test was used as a 
statistic summarizing the significance of each group of SNPs mapped to a specific gene. 
The significance of the SNP-set statistic was determined via 10,000 permutations. The 
method of Benjamini and Hochberg [75] was used to compute FDR-adjusted p-values 
[76].    
      
 
Primary Aim Three 
 
Identify potential candidate genes through identifying copy number 
variations that associate with the risk of secondary breast cancer.   
 
      For each SNP marker, summary signals were computed using dChip SNP 
software [77]. These signals were subsequently reference normalized [78]. Fore each 
marker, the median and inter-quartile range of signal values across controls was 
computed. Then, for each subject, a standardized difference was computed for each 
marker by subtracting the median among controls and dividing by the inter-quartile range 
among controls. 
 
      A Bayesian segmentation algorithm [79, 80] was used to segment the 
standardized difference profile of each chromosome in each subject. Segments with fewer 
than 25% of standardized differences being positive were identified as in silico regions of 
loss and segments with at least 75% of standardized differences being positive were 
identified as in silico regions of gain.     
 
      Finally, the segmentation results of individuals were used to segment the genome 
into regions with distinct patterns of gain/loss across the entire cohort. For each region 
with at least 5 subjects with an in silico gain or loss, we used Fisher’s test to explore the 
association of in silico copy number with case-controls status.  
 
 
Secondary Aim 
 
Explore the association between lifestyle characteristics (hormone use, 
pregnancy, lactation), family history and the occurrence of breast cancer.  
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      Descriptive analyses of cases and controls were conducted on the following 
variables: age, age at Hodgkin diagnosis, years since HL diagnosis, radiation, 
chemotherapy, age at menses, age of hormone initiation, age at menopause, age at first 
pregnancy and time from HL diagnosis and first pregnancy. Two sample t test was used 
to compute the p values. 
 
      Frequency tables were generated for menses status, use of hormone therapy and 
status of pregnancy, and simple logistic regression was used to evaluate the association 
between these variables and case-control status.  
 
      In addition, log-linear regression was used to evaluate the differences between 
case and control in number of pregnancies and number of live births. This part of the 
analyses was conducted using SAS version 9.1 (SAS Institute, 2003).  
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CHAPTER 4. RESULTS 
 
 
Introduction 
 
Data obtained over the course of this study are presented in this chapter. The 
results are presented according to the study aims. 
 
 
Description of the Sample 
 
 
Treatment Characteristics 
 
The study sample consisted of 48 women, from whom blood was collected and 
analyzed for global gene expression and genotype. The women who developed secondary 
breast cancer (cases) were matched with women who did not develop secondary breast 
cancer (controls) according to radiation dose, maximum alkylating chemotherapy dose, 
age at diagnosis and time since diagnosis. The cases and controls were not statistically 
different in current age, age at HL diagnosis and time since HL diagnosis as described in 
Table 4.1. Treatment variables of  mediastinal/mantel radiation and maximum dose of 
alkylating chemotherapy were well matched. Total radiation dose was the most 
significant matching variable and ranged from 41 to 20 Gy among cases with a median 
dose of 35.5 Gy.; radiation dose for the controls ranged from 15 to 41.7 Gy with a median 
dose of 35 Gy. Alkylating chemotherapy total dose was the second most significant 
matching variable because the induction of premature menopause that is associated with 
alkylating chemotherapy is thought to be a protective mechanism against the 
development of breast cancer. Ten of the 13 cases (76.9%) received alkylating therapy; 
24 of the 35 controls (68.5 %) received alkylating therapy. The cases and controls were 
not matched on pelvic and/or para-aortic radiation; however, it is important to determine 
this potential protective effect. Only 1 case (7%) received pelvic radiation and 8 cases 
received para-aortic which would have a smaller radiation scatter to the ovaries. In 
comparison, 16 controls (45.7%) had pelvic radiation of which 4 of the 16 received 
combined para-aortic and pelvic radiation, 11 controls received para-aortic radiation, 7 
controls received no pelvic or para-aortic radiation.  
 
 
Reproductive and Family Characteristics 
 
Each woman also completed a demographic form that included items regarding 
her hormonal use, reproductive history, and cancer family history. Differences between 
cases and controls on variables of menses, menopause, hormonal therapy, age at first 
pregnancy, and time from HL to first pregancy are listed in Table 4.2. There were no 
statistical differences between the cases and controls in the age of menses, current status 
of menses, or use of hormonal therapy. There is a statistical difference in age of 
menopause between the cases and controls, 16 controls (45.7%) who received pelvic  
37 
 
Table 4.1 Demographic Data: Current Age, Age at Time of Diagnosis and Years Since 
Diagnosis For Study Participants Who Did and Did Not Develop Secondary Breast 
Cancer. 
 
 
Study Sample 
n=48 
With Breast 
Cancer 
n=13 
Without 
Breast Cancer 
n=35 
p value 
Age in yrs  
(mean ± SD)            
40.2 ± 5.6 41.9 ± 6.7 39.6 ± 5.2 0.2181 
 
Age at Hodgkin 
Diagnosis  
(mean ± SD)            
14.3 ± 3.2 14.6 ± 2.1 14.3 ± 3.3 0.8127 
 
Years Since HL 
Diagnosis   
(mean ± SD)            
26 ± 5.9 27.5 ± 5.2 25.4 ± 6.01 0.2722 
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Table 4.2 Demographic Data: Age at Menses, Menopause, and Hormonal Use, 
According to Study Participants Who Did and Did Not Develop Secondary Breast 
Cancer.  
 
 
Study 
Sample 
n=48 
With Breast 
Cancer 
n=13 
Without Breast 
Cancer 
n=35 
P-value* 
Age at Menses 
(mean ± SD)            
12.7 12.8 ± 1.4 12.7 ± 2.3 0.8387 
Age at Menopause 
(mean ± SD)            
34 38.3 ± 2.5 32.1 ± 9.6 0.0191 
Currently Having 
Menses 
Yes=20 
No=28 
Yes=4 
No=9 
Yes=16 
No=19 
0.3544 
Use of Hormones 
(mean ± SD)            
48 13 35 NA 
Age Started 
Hormones 
(mean ± SD)            
21.6 22.9 ± 6.5 21.1 ± 7.7 0.4995 
 
Age Stopped 
Hormones 
(mean ± SD)            
32.6 32.8 ± 8.3 32.4 ± 7.7 0.9030 
 
Age at 1
st
 
Pregnancy 
(mean ± SD)            
25.4 26.5 ± 3.5 24.9 ± 4.6 0.3508 
Time from HL to 
1
st
 Pregnancy 
(mean ± SD)            
10.6 11.4 ± 3.1 9.9 ± 5.0 0.3992 
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radiation experienced the earliest onset of menopause with an average of 27.8 years of 
age (range 16-40), while only 3 of the 16 continue (28.7%) to have menses. All of the 
cases and controls reported hormonal use with no differences in the ages that hormones 
were initiated or discontinued. There was no statistical difference in age at first 
pregnancy or time from Hodgkin diagnosis and first pregnancy between the cases and 
controls. Reproductive history outlined in Table 4.3 shows that overall 31 (64.5%) of the 
cases and controls reported at least one pregnancy, with 76.7% of the cases becoming 
pregnant and 60% of the controls becoming pregnant. Overall the cases and controls 
reported 69 pregnancies and 53 live births with the controls having the highest number of 
lost pregnancies. While the controls reported higher rates of pregnancy difficulties with a 
lower number of pregnancies and live births; differences in reproductive history were not 
statistically significant. 
 
Family history of cancer was collected by self-report form the cases and controls. 
Eleven of the 13 cases (84.6%) reported a family history of cancer in a first or second 
degree family member. Five of the 11 (45%) cases reported among first degree relatives 
included: breast, prostate, esophageal, and skin. Among these 11 cases, the most common 
cancers among second degree relatives included: lung, breast, prostate, and lymphoma.  
 
Thirty one of the 35 controls (88.5%) reported a family history of cancer in a first 
or second degree family member. Fourteen of the 31 (45%) controls had a first degree 
family member with cancer with breast being the most frequent followed by lymphoma, 
skin, and lung. The most common cancers among second degree relatives included: 
lymphoma, breast, and prostate.   
 
 
Breast Cancer Characteristics Among Cases 
 
For the women with breast cancer, histology and hormonal status of their breast 
cancer was collected from pathology report if available or self report. In addition, a 
retrospective chart review collected additional information related to breast cancer 
occurrence including age at breast cancer diagnosis in comparison to Hodgkin diagnosis, 
and time from radiation to diagnosis of breast cancer. The average age of secondary 
breast cancer among the cases occurred at 36.5 ± 6.7 years of age with a range of 27.2- 
51 years of age. The time from radiation exposure to the development of secondary breast 
cancer among the cases is 21.3 ± 5.8 years after radiation with a range of 12-34 years. 
The range of 34 years is the result of an outlier and if excluded the range would be 12-27 
years with a mean of 20.2 ± 4.5 years from radiation to the development of breast cancer. 
There was no difference in the location of the breast cancer (right vs. left breast) and the 
tumors were predominately  infiltrating ductal carcinoma. The tumor estrogen, 
progesterone, and HER-2 statuses are unknown in 3 of the cases. The location, histology, 
and expression are detailed for each case in Table 4.4.  
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Table 4.3 Demographic Data: Reproductive History According to Study Participants 
Who Did and Did Not Develop Secondary Breast Cancer.  
 
 
Study Sample 
n=48 
With Breast 
Cancer 
n=13 
Without Breast 
Cancer 
n=35 
P-Value 
(95% CI) 
Achieving 
Pregnancy 
31 
Yes=10 
No=3 
 
Yes=21 
No=14 
 
0.2827 
(0.105, 1.931) 
Number of 
Pregnancies 
(mean ± SD)       
69 1.5 ± 1.2 1.4± 1.4 
0.7223 
(0.492,1.393) 
 
Number of 
Live Births 
(mean ± SD)       
53 1.3 ± 0.9 1.0 ± 1.0 
0.7223 
(0.347, 1.101) 
Breast Feeding 30 
Yes=3 
No=7 
Yes=8 
No=12 
0.5934 
(0.307, 7.872) 
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 Table 4.4 Breast Cancer Characteristics. 
 
Location of 
breast cancer 
Histology Estrogen Progesterone Her-2 
Bilateral 
Adenocarcinoma: 
Infiltrating ductal 
+ - - 
Left Breast Infiltrating ductal Unknown   
Left Breast  Infiltrating ductal Unknown   
Left Breast Infiltrating ductal + + - 
Right Breast Infiltrating ductal + + - 
Left Breast Infiltrating lobular + + + 
 
Right breast  
Invasive ductal - - - 
Left Breast Infiltrating ductal + + + 
Right Breast Infiltrating ductal - - Unknown 
Right Breast Infiltrating ductal + - + 
Left Breast Adenocarcinoma + - - 
Right Breast Ductal in Situ Unknown   
Left Breast Infiltrating ductal + - + 
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Primary Aim One 
 
Assess whether global gene expression profiles differ between two groups of 
radiated pediatric Hodgkin lymphoma survivors with and without the development 
of secondary breast cancer.  
 
The analysis identified 100 differentially expressed genes (p ? 0.0015; FDR ? 
0.68) and 12 pathways that showed significant gene-set enrichment (p ? 0.05; FDR ? 
0.57).  
In an analysis that ignored matching of individual cases to their selected 
controls using unmatched ranksum found genes of significance and 12 Affymetrix-
defined pathways from 233 identified pathways with a statistical difference between 
cases and control were observed. The pathyways of significance as well as the test 
statistic, permutation p value for the pathway, and false discovery rate (q) are given in 
Table 4.5; p ? 0.05: FRD ? 0.57. The pathways were generated from KEGG, a complete 
computer representation of the cell, the organism, and the biosphere, which will enable 
computational prediction of higher-level complexity of cellular processes and organism 
behaviors from genomic and molecular information. KEGG is a recognized 
bioinformatics data base and is part of the research projects of the Kanehisa Laboratories 
in the Bioinformatics Center of Kyoto University and the Human Genome Center of the 
University of Tokyo [81, 82] 
 
 The genes within the pathways were then explored for significance between the 
cases and controls. The pathway report files included gene specific results for genes in 
the pathways and a pathway p-value less than 0.10 per the method of Barry et al [74]. 
The analysis identified differentially expressed genes associated with the pathways and 
are reported in Table 4.6 ? FDR 0.57. The table is labeled with the associated pathway 
and includes the gene name and symbol, the case average of expression, the control 
average of expression, permutation p value, false discovery rate (q), and the Affymetric 
gene probe ID. A positive value of the test statistic indicates expression of the gene tends 
to be higher in controls than cases and is denoted in blue; conversely, a negative value of 
the test statistic indicated expression of the gene tended to be higher in cases than 
controls and is denoted in red. A gene summary statement is also given and was retrieved 
from Entrez Gene; a database designed to give detailed gene information and is linked 
with relevant databases for additional reference [83]. This analysis provides a list of 
genes of significant interest for function and their association with the phenotype and 
became genes of high interest in the genotype analysis.  It is noted that many of the genes 
are involved in multiple pathways that are significant within this analysis. Additionally, 
the same gene may be reported multiple times within a pathway due to gene splicing and 
expressed as differences in the gene isoforms, which may be verified with the Affymetric 
probe ID.  
 
The 12 pathways of significance are involved in amino acid metabolism, 
metabolism of cofactors and vitamins, biosynthesis of secondary metabolites, folding, 
sorting, and degradation of proteins, translation, and DNA replication and repair. Within 
these pathways, the global gene analysis found significant differences in gene expression 
between the cases and controls; however, each of these genes has a high false discovery  
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Table 4.5 12 Affymetrix-Defined Pathways of Significance. 
 
Defined Pathway Test Stat Perm. p. 
False 
Discovery (q) 
Methionine Metabolism 50.67365 0.0015 0.3495 
Selenoamino Acid Metabolism 55.48675 0.0051 0.5736 
Phenylalanine, Typrosine and 
Tryptophan biosynthesis 
39.28965 0.014 0.5736 
Alkaloid Biosynthesis 24.16919 0.014 0.5736 
Aminoacyl-tRNA Biosynthesis 86.91439 0.0177 0.5736 
Nicotinate and Nicotinamide 
Metabolism 
70.03519 0.0263 0.5736 
One Carbon Pool by Folate 58.43735 0.0314 0.5736 
Tetracycline Biosynthesis 19.23147 0.0336 0.5736 
Type II Secretion System 7.301847 0.0413 0.5736 
Histidine Metabolism 111.7057 0.0415 0.5736 
DNA Polymerase 28.78765 0.0452 0.5736 
Phenylalanine Metabolism 105.2655 0.0478 0.5736 
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Table 4.6 Significant Genes Associated with Designated Pathways.  Red denotes a  
higher gene expression in cases, while blue denotes higher gene expression in controls. 
 
Gene Name 
(Gene Symbol) 
Case 
Average 
Control 
Average 
Perm P q Probe-set ID 
Significant 
Pathways 
MARS 
Methionine-tRNA 
synthetase 
Location 12q13.2 
2098.546 2500.1472 0.0077 0.70 213671_s_at 
Methionine 
Metabolism 
Selenoamino acid 
Metabolism 
Aminoacyl-tRNA 
biosymthesis 
Gene Summary: Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their 
cognate amino acids. The protein encoded by this gene belongs to the class I family of tRNA 
synthetases. 
TRDMT1 
tRNA aspartic acid 
methyl-transferase 1 
Location 10p15.1 
451.7462 371.95833 0.01 0.70 206308_at 
Methionine 
Metabolism 
Gene Summary: CpG methylation is an epigenetic modification that is important for embryonic 
development, imprinting, and X-chromosome inactivation. This gene encodes a protein with similarity 
to DNA methyltransferases, but this protein does not display methyltransferase activity. The protein 
strongly binds DNA, suggesting that it may mark specific sequences in the genome. Alternative splicing 
results in multiple transcript variants encoding different isoforms.  
MARS 
Methionine-tRNA 
synthetase 
Location 12q13.2 
202.5 274.73889 0.02 0.71 213672_at 
Methionine 
Metabolism 
Selenoamino acid 
Metabolism 
Aminoacyl-tRNA 
biosymthesis 
Gene Summary: Previously described 
MARS2 
methionine-tRNA 
synthetase 2 
(mitochondrial) 
Location 2q33 
182.4846 239.97222 0.023 0.71 243529_at 
Methionine 
MetabolisSelenamin
o acid Metabolism 
Aminoacyl-tRNA 
iosynthesis 
Gene Summary: Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their 
cognate amino acids. The protein encoded by this gene belongs to the class I family of tRNA 
synthetases 
MAT2B methionine 
adenosylransferase 
II, beta Location 
5q34-q35.1 
21324.31 17708.381 0.027 0.71 217993_s_at 
Methionine 
Metabolism 
Selenoamino acid 
Metabolism 
Gene Summary: The protein encoded by this gene belongs to the methionine adenosyltransferase 
(MAT) family. MAT catalyzes the biosynthesis of S-adenosylmethionine from methionine and ATP. 
This protein is the regulatory beta subunit of MAT. Alternative splicing occurs at this locus and two 
transcript variants encoding distinct isoforms have been identified.  
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Table 4.6 Continued.   
 
Gene Name 
(Gene Symbol) 
Case 
Average 
Control 
Average 
Perm P q Probe-set ID 
Significant 
Pathways 
MARS  
Methionine-tRNA 
synthetase Location 
12q13.2  
1483.392 1741.5194 0.037 0.72 201475_x_at 
Methionine 
Metabolism 
Aminoacyl-tRNA 
biosynthesis 
Gene Summary: Previously described. 
MTR 5-
methyltetrahydrofol
ate- homocysteine 
methyltransferase 
Location 1q43 
11136.008 1417.133 0.0374 0.727 203774_at      
Methionine 
Metabolism 
One carbon pool by 
folate 
Gene Summary: MTR encodes the enzyme 5-methyltetrahydrofolate-homocysteine methyltransferase. 
This enzyme, also known as cobalamin-dependent methionine synthase, catalyzes the final step in 
methionine biosynthesis. Mutations in MTR have been identified as the underlying cause of 
methylcobalamin deficiency complementation group G. 
DNMT3A  
DNA (cytosine-5-)-
methyltransferase 3 
alpha Location 2p23 
431.8462 494.2083 0.0416 0.728 244428_at      
Methionine 
Metabolism 
Gene Summary: CpG methylation is an epigenetic modification that is important for embryonic 
development, imprinting, and X-chromosome inactivation. Studies in mice have demonstrated that 
DNA methylation is required for mammalian development. This gene encodes a DNA 
methyltransferase that is thought to function in de novo methylation, rather than maintenance 
methylation. The protein localizes to the cytoplasm and nucleus and its expression is developmentally 
regulated. Alternative splicing results in multiple transcript variants encoding different isoforms.  
PAPSS2 3'-
phosphoadenosine 
5'-phosphosulfate 
synthase 2 Location 
10q23-q24 
139.1923 91.25  0.016 0.704 203059_s_at    
Selenoamino acid 
Metabolism 
PAPSS2 3'-
phosphoadenosine 
5'-phosphosulfate 
synthase 2 Location 
10q23-q24 
535.6385 469.7139     0.0262    0.717 203060_s_at    
Selenoamino acid 
Metabolism 
Gene Summary: Sulfation is a common modification of endogenous (lipids, proteins, and 
carbohydrates) and exogenous (xenobiotics and drugs) compounds. In mammals, the sulfate source is 
3'-phosphoadenosine 5'-phosphosulfate (PAPS), created from ATP and inorganic sulfate. Two different 
tissue isoforms encoded by different genes synthesize PAPS. This gene encodes one of the two PAPS 
synthetases. 
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Table 4.6 Continued.   
 
Gene Name 
(Gene Symbol) 
Case 
Average 
Control 
Average 
Perm P q Probe-set ID 
Significant 
Pathways 
MARS 
Methionine-tRNA 
synthetase Location 
12q13.2 
1483.392 1741.5194 0.037 0.72 201475_x_at 
Selenoamino acid 
Metabolism 
Gene Summary: Previously described 
YARS  
tyrosyl-tRNA 
synthetase Location 
1p35.1                        
1755.892 2400.817  0.0029 0.69 212048_s_at    
Phenylalanine, 
tyrosine tryptophan 
biosynthesis 
Aminoacyl-tRNA 
biosynthesis 
Gene Summary: Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate 
amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in 
tRNAs, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in 
evolution. Tyrosyl-tRNA synthetase belongs to the class I tRNA synthetase family. Cytokine activities 
have also been observed for the human tyrosyl-tRNA synthetase, after it is split into two parts, an N-
terminal fragment that harbors the catalytic site and a C-terminal fragment found only in the 
mammalian enzyme. The N-terminal fragment is an interleukin-8-like cytokine, whereas the released 
C-terminal fragment is an EMAP II-like cytokine.  
FARS2 
phenylalanine-
tRNA synthetase 2 
(mitochondrial) 
Location 6p25.1 
569.8       697.2167 0.0197    0.70 204282_s_at    
Phenylalanine, 
tyrosine 
tryptophan 
biosynthesis 
Aminoacyl-tRNA 
biosynthesis 
Gene Summary: Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their 
cognate amino acids. This gene encodes a phenylalanine-tRNA synthetase (PheRS) localized to the 
mitochondrion which consists of a single polypeptide chain, unlike the (alpha-beta)2 structure of the 
prokaryotic and eukaryotic cytoplasmic forms of PheRS. Structure analysis and catalytic properties 
indicate mitochondrial PheRSs may constitute a class of PheRS distinct from the enzymes found in 
prokaryotes and in the eukaryotic cytoplasm.  
ENO2 
enolase 2 (gamma, 
neuronal) 
215.7615 296.916  0.0199 0.70 201313_at      
Phenylalanine, 
tyrosine 
tryptophan 
biosynthesis 
Gene Summary: This gene encodes one of the three enolase isoenzymes found in mammals. This 
isoenzyme, a homodimer, is found in mature neurons and cells of neuronal origin. A switch from alpha 
enolase to gamma enolase occurs in neural tissue during development in rats and primates. 
DDC dopa 
decarboxylase 
(aromatic L-amino 
acid decarboxylase) 
Location 7p11 
63.95385 28.15833     0.0067 0.69 214347_s_at    
Alkaloid 
biosynthesis 
Histidine 
Metabolism 
Phenylalanine 
Metabolism 
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Table 4.6 Continued.  
 
Gene Name 
(Gene Symbol) 
Case 
Average 
Control 
Average 
Perm P q Probe-set ID 
Significant 
Pathways 
MARS 
Methionine-tRNA 
synthetase 
Location 12q13.2 
2098.546 2500.1472 0.0077 0.70 213671_s_at 
Methionine 
Metabolism 
Selenoamino acid 
Metabolism 
Aminoacyl-tRNA 
biosymthesis 
Gene Summary: Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their 
cognate amino acids. The protein encoded by this gene belongs to the class I family of tRNA 
synthetases. 
TRDMT1 
tRNA aspartic acid 
methyl-transferase 1 
Location 10p15.1 
451.7462 371.95833 0.01 0.70 206308_at 
Methionine 
Metabolism 
Gene Summary: CpG methylation is an epigenetic modification that is important for embryonic 
development, imprinting, and X-chromosome inactivation. This gene encodes a protein with similarity 
to DNA methyltransferases, but this protein does not display methyltransferase activity. The protein 
strongly binds DNA, suggesting that it may mark specific sequences in the genome. Alternative splicing 
results in multiple transcript variants encoding different isoforms.  
MARS 
Methionine-tRNA 
synthetase 
Location 12q13.2 
202.5 274.73889 0.02 0.71 213672_at 
Methionine 
Metabolism 
Selenoamino acid 
Metabolism 
Aminoacyl-tRNA 
biosymthesis 
Gene Summary: Previously described 
MARS2 
methionine-tRNA 
synthetase 2 
(mitochondrial) 
Location 2q33 
182.4846 239.97222 0.023 0.71 243529_at 
Methionine 
MetabolisSelenamin
o acid Metabolism 
Aminoacyl-tRNA 
iosynthesis 
Gene Summary: Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their 
cognate amino acids. The protein encoded by this gene belongs to the class I family of tRNA 
synthetases. 
MAT2B 
 methionine 
adenosylransferase 
II, beta Location 
5q34-q35.1 
21324.31 17708.381 0.027 0.71 217993_s_at 
Methionine 
Metabolism 
Selenoamino acid 
Metabolism 
Gene Summary: The protein encoded by this gene belongs to the methionine adenosyltransferase 
(MAT) family. MAT catalyzes the biosynthesis of S-adenosylmethionine from methionine and ATP. 
This protein is the regulatory beta subunit of MAT. Alternative splicing occurs at this locus and two 
transcript variants encoding distinct isoforms have been identified.  
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Table 4.6 Continued.   
 
Gene Name 
(Gene Symbol) 
Case 
Average 
Control 
Average 
Perm P q Probe-set ID 
Significant 
Pathways 
MARS  
Methionine-tRNA 
synthetase Location 
12q13.2  
1483.392 1741.5194    0.037 0.72 201475_x_at    
Methionine 
Metabolism 
Aminoacyl-tRNA 
biosynthesis 
Gene Summary: Previously described 
MTR 5-
methyltetrahydrofol
ate- homocysteine 
methyltransferase 
Location 1q43 
11136.008 1417.133 0.0374 0.727 203774_at      
Methionine 
Metabolism 
One carbon pool by 
folate 
Gene Summary: MTR encodes the enzyme 5-methyltetrahydrofolate-homocysteine methyltransferase. 
This enzyme, also known as cobalamin-dependent methionine synthase, catalyzes the final step in 
methionine biosynthesis. Mutations in MTR have been identified as the underlying cause of 
methylcobalamin deficiency complementation group G. 
DNMT3A  
DNA (cytosine-5-)-
methyltransferase 3 
alpha Location 2p23 
431.8462 494.2083 0.0416 0.728 244428_at      
Methionine 
Metabolism 
Gene Summary: CpG methylation is an epigenetic modification that is important for embryonic 
development, imprinting, and X-chromosome inactivation. Studies in mice have demonstrated that 
DNA methylation is required for mammalian development. This gene encodes a DNA 
methyltransferase that is thought to function in de novo methylation, rather than maintenance 
methylation. The protein localizes to the cytoplasm and nucleus and its expression is developmentally 
regulated. Alternative splicing results in multiple transcript variants encoding different isoforms.  
PAPSS2 3'-
phosphoadenosine 
5'-phosphosulfate 
synthase 2 Location 
10q23-q24 
139.1923 91.25  
0.0168
  
      
0.704 
203059_s_at    
Selenoamino acid 
Metabolism 
PAPSS2 3'-
phosphoadenosine 
5'-phosphosulfate 
synthase 2 Location 
10q23-q24 
535.6385 469.7139      0.0262    0.717 203060_s_at    
Selenoamino acid 
Metabolism 
Gene Summary: Sulfation is a common modification of endogenous (lipids, proteins, and 
carbohydrates) and exogenous (xenobiotics and drugs) compounds. In mammals, the sulfate source is 
3'-phosphoadenosine 5'-phosphosulfate (PAPS), created from ATP and inorganic sulfate. Two different 
tissue isoforms encoded by different genes synthesize PAPS. This gene encodes one of the two PAPS 
synthetases. 
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Table 4.6 Continued.   
 
Gene Name 
(Gene Symbol) 
Case 
Average 
Control 
Average 
Perm P q Probe-set ID 
Significant 
Pathways 
TYR  
tyrosinase 
(oculocutaneous 
albinism IA) 
Location 11q14-
q21 
159.9538 109.6667 0.0133 0.70 206630_at      
Alkaloid 
biosynthesis 
AARS  
alanyl-tRNA  
synthetase Location 
16q22 
1105.031 1357.4944 0.0039 0.69 201000_at      
Aminoacyl-tRNA 
biosynthesis 
Gene Summary: tRNA synthases are the enzymes that interpret the RNA code and attach specific 
aminoacids to the tRNAs that contain the cognate trinucleotide anticodons. They consist of a catalytic 
udomain which interacts with the amino acid acceptor-T psi C helix of the tRNA, and a second domain 
which interacts with the rest of the tRNA structure. 
LARS  
l  lecyl-tRNA 
synthetase Location 
5q32 
2189.269 2854.6 0.0084 0.70 217810_x_at    
Aminoacyl-tRNA 
biosynthesis 
Gene Summary: This gene encodes a cytosolic leucine-tRNA synthetase, a member of the class I 
aminoacyl-tRNA synthetase family. The encoded enzyme catalyzes the ATP-dependent ligation of L-
leucine to tRNA(Leu). It is found in the cytoplasm as part of a multisynthetase complex and interacts 
with the arginine tRNA synthetase through its C-terminal domain. 
LARS2 
leucyl-tRNA 
synthetase 2, 
mitochondrial 
Location 3p21.3 
260.8538 297.0306  0.0492 0.73 34764_at       
Aminoacyl-tRNA 
biosynthesis 
Gene Summary: This gene encodes a class 1 aminoacyl-tRNA synthetase, mitochondrial leucyl-
tRNA synthetase. Each of the twenty aminoacyl-tRNA synthetases catalyzes the aminoacylation of a 
specific tRNA or tRNA isoaccepting family with the cognate amino acid.  
HARS  
histidyl-tRNA 
synthetase Location 
5q31. 
1129.131 1352.417  0.0554 0.74 202042_at      
Aminoacyl-tRNA 
biosynthesis 
Histidine 
Metabolism 
Gene Summary: Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their 
cognate amino acids. The protein encoded by this gene is a cytoplasmic enzyme which belongs to the 
class II family of aminoacyl-tRNA synthetases. The enzyme is responsible for the synthesis of 
histidyl-transfer RNA, which is essential for the incorporation of histidine into proteins. 
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Table 4.6 Continued.   
 
Gene Name 
(Gene Symbol) 
Case 
Average 
Control 
Average 
Perm P q Probe-set ID 
Significant 
Pathways 
NMNAT2 
nicotinamide 
nucleotide 
adenylyltransferase 
2 Location 1q25  
155.7385 97.59167 0.001     0.67  1552712_a_at   
Nicotinate and 
nicotinamide 
metabolism 
Gene Summary: This gene product belongs to the nicotinamide mononucleotide adenylyltransferase 
(NMNAT) enzyme family, members of which catalyze an essential step in NAD (NADP) biosynthetic 
pathway. 
NT5C3 5'-
nucleotidase, 
cytosolic III 
Location 7p14.3 
9632.208 6214.1278 0.032 0.72 223298_s_at     
Nicotinate and 
nicotinamide 
metabolism 
Gene Summary: Pyrimidine 5-prime-nucleotidase (P5N; EC 3.1.3.5), also called uridine 5-prime 
monophosphate hydrolase (UMPH), catalyzes the dephosphorylation of the pyrimidine 5-prime 
monophosphates UMP and CMP to the corresponding nucleosides 
PBEF1  
pre-B-cell colony 
enhancing factor 1 
pre-B cell 
enhancing factor 1 
pseudogene 
Location 7q22.2 /// 
10p11.21 
42190.62    34318.536    0.043 0.7     217739_s_at     
Nicotinate and 
nicotinamide 
metabolism 
Gene Summary: This gene encodes a protein that catalyzes the condensation of nicotinamide with 5-
phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, one step in the biosynthesis of 
nicotinamide adenine dinucleotide. The protein is an adipokine that is localized to the bloodstream and 
has various functions, including the promotion of vascular smooth muscle cell maturation and 
inhibition of neutrophil apoptosis. It also activates insulin receptor and has insulin-mimetic effects, 
lowering blood glucose and improving insulin sensitivity. The protein is highly expressed in visceral fat 
and serum levels of the protein correlate with obesity. This gene has a pseudogene on chromosome 10.  
NMNAT2 
nicotinamide 
nucleotide 
adenylyltransferase 
2 Location 1q25         
41.99231 20.952778 0.046 
        
0.73 
209755_at      
Nicotinate and 
nicotinamide 
metabolism 
Gene Summary: Previously described 
NT5E 5'-
nucleotidase,  ecto 
(CD73) Location 
6q14-q21 
67.71538 99.030556 0.049 0.73 227486_at          
Nicotinate and 
nicotinamide 
metabolism 
Gene Summary: Ecto-5-prime-nucleotidase (5-prime-ribonucleotide phosphohydrolase; EC 3.1.3.5) 
catalyzes the conversion at neutral pH of purine 5-prime mononucleotides to nucleosides, the preferred 
substrate being AMP. The enzyme consists of a dimer of 2 identical 70-kD subunits bound by a 
glycosyl phosphatidyl inositol linkage to the external face of the plasma membrane. The enzyme is used 
as a marker of lymphocyte differentiation. Consequently, a deficiency of NT5 occurs in a variety of 
immunodeficiency diseases 
 
51 
 
Table 4.6 Continued.   
 
Gene Name 
(Gene Symbol) 
Case 
Average 
Control 
Average 
Perm P q Probe-set ID 
Significant 
Pathways 
TYMS Thymidylate 
synthetase Location 
18p11.32 
128.5154 187.9 0.006 0.69 243016_at      
One carbon pool by 
folate 
Gene Summary: Thymidylate synthase (TYMS, or TS; EC 2.1.1.45) uses the 5,10-
methylenetetrahydrofolate (methylene-THF) as a cofactor to maintain the dTMP (thymidine-5-prime 
monophosphate) pool critical for DNA replication and repair. The enzyme has been of interest as a 
target for cancer chemotherapeutic agents. It is considered to be the primary site of action for 5-
fluorouracil, 5-fluoro-2-prime-deoxyuridine, and some folate analogs. 
DHFR///LOC64350
9 dihydrofolate 
reductase /// similar 
to Dihydrofolate 
reductase Location 
5q11.2-q13.2 /// 
18q11.2 
240.7385 311.76389 0.008 0.70 48808_at       
One carbon pool by 
folate 
Gene Summary: Dihydrofolate reductase converts dihydrofolate into tetrahydrofolate, a methyl group 
shuttle required for the de novo synthesis of purines, thymidylic acid, and certain amino acids. While 
the functional dihydrofolate reductase gene has been mapped to chromosome 5, multiple intronless 
processed pseudogenes or dihydrofolate reductase-like genes have been identified on separate 
chromosomes  
SHMT1  
serine 
hydroxymethyltransf
erase 1 (soluble) 
Location 17p11.2 
119.7846 80.466667 0.338 0.72 217304_at      
One carbon pool by 
folate 
Gene Summary: This gene encodes the cellular form of serine hydroxymethyltransferase, a pyridoxal 
phosphate-containing enzyme that catalyzes the reversible conversion of serine and tetrahydrofolate to 
glycine and 5,10-methylene tetrahydrofolate. This reaction provides one carbon units for synthesis of 
methionine, thymidylate, and purines in the cytoplasm. 
TYMS 
thymidylate 
synthetase Location 
18p11.32 
31.77692 21.111111  0.044 0.73 217684_at      
One carbon pool by 
folate 
Gene Summary: Previously described 
ACACA 
 acetyl-Coenzyme A 
carboxylase alpha 
Location 17q21 
198.8846 352.24167 0.0008 0.67 212186_at      
Tetracycline 
biosynthesis 
Gene Summary: Acetyl-CoA carboxylase (ACC) is a complex multifunctional enzyme system. ACC 
is a biotin-containing enzyme which catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the 
rate-limiting step in fatty acid synthesis. There are two ACC forms, alpha and beta, encoded by two 
different genes. ACC-alpha is highly enriched in lipogenic tissues. The enzyme is under long term 
control at the transcriptional and translational levels and under short term regulation by the 
phosphorylation/dephosphorylation of targeted serine residues and by allosteric transformation by 
citrate or palmitoyl-CoA. 
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Table 4.6 Continued.   
 
Gene Name 
(Gene Symbol) 
Case 
Average 
Control 
Average 
Perm P q Probe-set ID 
Significant 
Pathways 
ACACB  
acetyl-Coenzyme A 
carboxylase beta 
Location 12q24.11 
212.2308 294.34722 0.033  0.72 49452_at       
Tetracycline 
biosynthesis 
Gene Summary: Acetyl-CoA carboxylase (ACC) is a complex multifunctional enzyme system. ACC 
is a biotin-containing enzyme which catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the 
rate-limiting step in fatty acid synthesis. ACC-beta is thought to control fatty acid oxidation by means 
of the ability of malonyl-CoA to inhibit carnitine-palmitoyl-CoA transferase I, the rate-limiting step in 
fatty acid uptake and oxidation by mitochondria. ACC-beta may be involved in the regulation of fatty 
acid oxidation, rather than fatty acid biosynthesis. 
DCTD  
dCMP deaminase 
Location 4q35.1 
785.7692 943.88889 0.011 0.70 201572_x_at    
Type II section 
system 
DCTD  960.6692 1117.6056 0.105 0.78 210137_s_at    
Type II section 
system 
Gene Summary: The protein encoded by this gene catalyzes the deamination of dCMP to dUMP, the 
nucleotide substrate for thymidylate synthase. The encoded protein is allosterically activated by dCTP 
and inhibited by dTTP, and is found as a homohexamer. This protein uses zinc as a cofactor for its 
activity. 
ABP1  61.82308 27.313889   0.005 0.69 242452_at      
Histidine 
Metabolism 
Phenylalanine 
Metabolism    
ABP1 76.28462 117.71667 0.007 0.70 229156_s_at    
Histidine 
Metabolism 
Phenylalanine 
Metabolism 
ABP1 940.4462 1124.4139 0.026  0.71 236401_at      
Histidine 
Metabolism 
Phenylalanine 
Metabolism 
ABP1  
Amiloride binding 
protein 1 (amine 
oxidase (copper-
containing) Location 
7q34-q36 
2142.508 2590.5944 0.033 0.72 236583_at      
Histidine 
Metabolism 
Phenylalanine 
Metabolism     
Gene Summary: This gene encodes a membrane glycoprotein that is expressed in many epithelium-
rich and/or hematopoietic tissues and oxidatively deaminates putrescine and histamine. The protein may 
play a role in controlling the level of histamine and/or putrescine in these tissues. It also binds to and is 
inhibited by amiloride, a diuretic that acts by closing epithelial sodium ion channels.  
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Table 4.6 Continued.   
 
Gene Name 
(Gene Symbol) 
Case 
Average 
Control 
Average 
Perm P q Probe-set ID 
Significant 
Pathways 
MAOA 157.7385 72.35 0.0121 0.70 A 212741_at    
Histidine 
Metabolism 
Phenylalanine 
Metabolism 
MAOA monoamine 
oxidase Location 
Xp11.3 
143.4769 104.04167 0.021 0.70 234534_at      
Histidine 
Metabolism 
Phenylalanine 
Metabolism 
Gene Summary: This gene encodes monoamine oxidase A, an enzyme that degrades amine 
neurotransmitters, such as dopamine, norepinephrine, and serotonin. The protein localizes to the 
mitochondrial outer membrane. The gene is adjacent to a related gene on the opposite strand of 
chromosome X. Mutation in this gene results in monoamine oxidase deficiency. 
POLB Polymerase 
(DNA directed), 
beta Location 
8p11.2 
18.22308 35.7 0.005 0.69 234907_x_at    
DNA Polymerase 
 
Gene Summary: In eukaryotic cells, DNA polymerase beta (POLB) performs base excision repair 
(BER) required for DNA maintenance, replication, recombination, and drug resistance. 
POLS   
Polymerase (DNA 
directed) Sigma 
Location 5p15 
1525.169 1910.8167 0.005 0.69 202466_at      DNA Polymerase 
Gene Summary: The protein encoded by this gene is a DNA polymerase that is likely involved in 
DNA repair. In addition, the encoded protein may be required for sister chromatid adhesion.  
POLG 
Polymerase (DNA 
directed), gamma 
Location 15q25 
567.2154 754.58056 0.006 0.69 203366_at      DNA Polymerase 
PRDX2 
Phenylalanine 
Metabolism 
peroxiredoxin 2 
Location 19p13 
203.8846 155.89167 0.039 0.72 201006_at      
Phenylalanine 
Metabolism 
 
Gene Summary: This gene encodes a member of the peroxiredoxin family of antioxidant enzymes, 
which reduce hydrogen peroxide and alkyl hydroperoxides. The encoded protein may play an 
antioxidant protective role in cells, and may contribute to the antiviral activity of CD8(+) T-cells. This 
protein may have a proliferative effect and play a role in cancer development or progression. The 
crystal structure of this protein has been resolved to 2.7 angstroms.  
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rate, giving the expected proportion of false positives among the declared significant 
results and accounts for the testing of thousands of hypotheses simultaneously [75]. 
 
 
Primary Aim Two 
 
Assess whether genotypes differ between two groups of radiated pediatric 
Hodgkin lymphoma survivors with and without the development of secondary 
breast cancer.   
 
A total of 397,877 SNPs passed the variation requirement for detailed statistical 
analysis. At a p-value threshold of 0.001, the robust FDR estimate is 1, indicating that 
most or all SNPs are false discoveries. Due to the large number of SNP’s and false 
discovery rate of 1, the SNP’s  with a chi square p value < 0.001 were transformed into a 
minuslog P which is 10 based –log of the chi-square p values and described in Appendix 
E. 
 
To determine the genes associated with the SNP’s of interest, a Geneset 
enrichment p-value file was created and consisted of 13, 090 genes, of which 574 had a 
p-vaule of ?0.05 and false discovery rate of 1.  This file gave the gene name, 
chromosome number, the start and end location of the gene, gamma test statics, 
permutation p value, and FDR Value. This file provided additional location of the gene 
chromosome and relationship to SNP.  
 
To visualize the results, a plot was created and corresponds to the –log10 p-value 
of the SNP which corresponds to having a chi-square p-value < 0.001. Each of the SNP’s 
having a –log10 p > than 3 (p < 0.001) is distinguished on the plot with a red dot and 
displayed for each chromosome in Figures 4.1-4.23. These figures mark clusters of 
SNP’s and their corresponding location and become those of highest interest. The 
chromosomes which displayed the highest number of significant SNP differences 
between cases and controls were chromosomes 5, 10, and 11.    
 
Chromosome 5 displays a significant SNP_1907286 (-log 10 p= 4.8) at position 
31786818 and is associated with the PDZD2 gene although not statically significant 
(p=0.49; FDR?1). Chromosome 10 had the largest number of SNP’s differentially 
expressed with a region of 6.1 kilobases containing 11 differentially expressed SNPs 
between the cases and controls. Two highly significant SNP’s within this region are 
SNP_A-2181577 (-log 10 p=3.97) and SNP_A-2006464 (-log 10 p=3.97) at position 
127481155 and 127485797 and statistically associated with the UROS gene (p=.001; 
FDR ?1). The most significant SNP within the region of chromosome 10 was SNP_A-
1842005 (-log 10 p= 3.98) at position 127508528 and statistically associated with the 
BCCIP gene (p=.001; FDR ?1).  Within this polymorphic region there were two other 
genes that were significant in the analysis, MMP21 (p=.001: FDR ?1) and DHX32 
(p=.001: FDR ?1). The analysis found the most significant SNPs, SNP_A-2294376 (-log 
10 p=5.1) and SNP_A-2209464 (-log 10 p=5.2), to be located on chromosome 11 at 
position 119148037 and 119149661 and associated with the genes TRIM29 (p=0.845)  
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Figure 4.1 Peak p-Values for Chromosome 1. 
 
 
 
 
 
Figure 4.2 Peak p-Values for Chromosome 2. 
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Figure 4.3 Peak p-Values for Chromosome 3. 
 
 
 
 
 
Figure 4.4 Peak p-Values for Chromosome 4. 
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Figure 4.5 Peak p-Values for Chromosome 5. 
 
 
 
 
 
Figure 4.6 Peak p-Values for Chromosome 6. 
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Figure 4.7 Peak p-Values for Chromosome 7. 
 
 
 
 
 
Figure 4.8 Peak p-Values for Chromosome 8. 
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Figure 4.9 Peak p-Values for Chromosome 9. 
 
 
 
 
 
Figure 4.10 Peak p-Values for Chromosome 10. 
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Figure 4.11 Peak p-Values for Chromosome 11. 
 
 
 
 
 
Figure 4.12 Peak p-Values for Chromosome 12 
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Figure 4.13 Peak p-Values for Chromosome 13. 
 
 
 
 
 
Figure 4.14 Peak p-Values for Chromosome 14. 
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Figure 4.15 Peak p-Values for Chromosome 15. 
 
 
 
 
 
Figure 4.16 Peak p-Values for Chromosome 16. 
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Figure 4.17 Peak p-Values for Chromosome 17. 
 
 
 
 
 
Figure 4.18 Peak p-Values for Chromosome 18. 
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Figure 4.19 Peak p-Values for Chromosome 19. 
 
 
 
 
 
Figure 4.20 Peak p-Values for Chromosome 20. 
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Figure 4.21 Peak p-Values for Chromosome 21. 
 
 
 
 
 
Figure 4.22 Peak p-Values for Chromosome 22. 
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Figure 4.23 Peak p-Values for Chromosome 23. (X chromosome) 
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and PVRL (p=0.142).  However, these genes were not statistically associated with the 
SNP in the Geneset enrichment file.  
 
 
Primary Aim Three 
 
Identify candidate copy number variants that may be associated with the risk 
of  secondary breast cancer.  
 
This analysis identified 130 in silico amplifications or deletions. Multiple cases 
and controls had common regions of amplification (gain) or deletion (loss) in sections of 
chromosomes 2, 14, and 15. In silico copy number variants were detected in 2q 37.3 for 5 
subjects, 14q11.2 for 8 subjects, and 15q11.2 for 24 subjects.  
 
There is some evidence that case-control status is associated with in silico copy 
number of a section of 14q11.2 and 15q11.2. Within 14q11.2, gain was observed in 3 of 
13 (23%) cases, 3 of 36 controls (8%), and 1 case had a deletion (p=0.069). Within 
15q11.2, gain was observed in 11 of 36 controls (30.5%) and no cases (0%), diploid 
status was inferred for 16 of 36 controls (44%) and 9 of 13 cases (69%) and loss was 
inferred for 4 of 13 cases (30.7%) and 9 of 36 controls (25%) (p=0.067). The copy  
number prevalence over the region of 14q11.2 is illustrated in Figure 4.24 and the 
correlated genes expression plots for chromosome 14 are given in Figure 4.25. 
 
The genes associated with copy number variation 14q11.2, OR4N4 and OR4Q3 
are olfactory genes known to be the largest gene family within the genome and known to 
regions of variability and have no known association with the study phenotype. 
 
The copy number prevalence over the region of 15q11.2 is depicted in Figure 
4.26.  Chromosome 15 had 19 Affymetric gene probe sets found to be within the region 
of copy number variation between those with a deletion, gain, or diploid within 15q11.2. 
The Affymetric gene probe set and corresponding gene are described in Table 4.7. From 
these probe sets, 19 expression plots were generated; however, only the genes with 
specific interest are depicted in Figures 4.27-32 and include PAK2, CYFIP1, NIPA1, 
NIPA2, TUBGCP5, and BCL8.   
 
The family history of breast cancer was then analyzed with consideration of copy 
number variation.  The analysis found no association with gain or no change within the 
region; however, there was an association (p=0.0392) as depicted in Table 4.8 with 
deletion within the 15q11.2 region and having a first degree relative with breast cancer. 
No association was found with second degree relative and copy number deletion. 
 
 
Summary of Results 
 
Aim one described the global gene expression between the cases and controls 
with defined Affymetric pathways and genes that were significantly differentially  
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Figure 4.24 Prevalence of Inferred Copy Number Variation among Cases and Controls 
within 14q11.2. 
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Figure 4.25 Gene Expression Correlated with Copy Number Variation at 14q11.2. (X – 
Case; O – Control) 
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Figure 4.26 Prevalence of Inferred Copy Number Variation among Cases and Controls 
within 15q11.2. (X – Case; O – Control) 
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 Table 4.7 Genes Associated with Copy Number Variation at 15q11.2. 
 
Probe Set Gene Symbol / Name 
208923_at               CYFIP1: Cytoplasmic FMR1 Interacting protein 
235083_at                  FLJ38359: hypothetical protein 
236283_x_at              
 
PAK2: CDKNIA activated kinase 2 
239899_at                  
 
RNF145: Ring finger protein 145 
1552696_at                
 
NIPA1: non imprinted in Prader Will Angleman Snydrome 1 
1556739_at                
FLJ35785: hypothetical protein 
LOC653125: Similar to glolgi autoantigen 
LOC653720: Golgi Subfamily a, 8A 
 
1560683_at                
 
BCL8: B-cell CLL/lymphoma 
1560684_x_at            
 
BCL8: B-cell CLL/lymphoma 
1564855_at                
 
LOC727924: hypothetical protein 
1564856_at                
 
LOC 727924: hypothetical protein 
1569013_at                LOC 96610: hypothetical protein 
212129_at                 
 
NIPA2: non imprinted in Prader Will Angleman Snydrome 2 
212133_at                 
 
NIPA2: non imprinted in Prader Will Angleman Snydrome 2 
214876_s_at             
 
TUBGCP5: Tubulin, gamma complex associated protein 5 
216193_at                  
 
LOC 440366: hect domain and RLD 2 pseudogene 
225752_at                  
 
NIPA1: non imprinted in Prader Will Angleman Snydrome 1 
226077_at                  
 
RNF 145: Ring finger protein 145 
227967_at                  
 
TUBGCP5: Tubulin, gamma complex associated protein 5 
234912_at                  
 
LOC 651964: hypothetical protein 
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Figure 4.27 Correlation of CYFIP1 Gene Expression and Copy Number Variation. (X – 
Case; O – Control) 
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Figure 4.28 Correlation of PAK2 Gene Expression and Copy Number Variation. (X – 
Case; O – Control) 
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Figure 4.29 Correlation of NIPA1 Gene Expression and Copy Number Variation. (X – 
Case; O – Control) 
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Figure 4.30 Correlation of NIPA2 Gene Expression and Copy Number Variation. (X – 
Case; O – Control) 
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Figure 4.31 Correlation of BCL8 Gene Expression and Copy Number Variation. (X – 
Case; O – Control) 
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Figure 4.32 Correlation of TUBGCP5 Gene Expression and Copy Number Variation.  
(X – Case; O – Control) 
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Table 4.8 Association of First Degree Breast Cancer Family History and Deletion at 
15q11.2.  95% Confidence. 
 
Parameter Estimate Limits p-Value 
Relative 1 9.499 1.092 135.406 0.0392 
Relative 2 2.730 0.380 20.335 0.4154 
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expressed between the cases and controls. This provided pathways and genes of interest 
in association with the phenotype of HL and breast cancer. The analysis found significant 
differences between the cases and controls in genes involved in amino acid metabolism, 
metabolism of cofactors and vitamins, biosynthesis of secondary metabolites, folding, 
sorting, and degradation of proteins, translation, and DNA replication and repair. 
Therefore, there are differences in the global gene expression between those with and 
without secondary breast cancer. 
 
             Aim two explored the genotype variability between cases and controls and found 
a large number of SNP variation and statistical differences between the genotype of those 
with and without secondary breast cancer. The most significant SNP variability between 
cases and controls was noted on chromosomes 5, 10, and 11. A region of genotype 
variability on chromosome 10 is of great interest due to the significant association with 
the BCCIP gene (p=.001) and the genes known interaction with BRCA2 and the 
phenotype of breast cancer.  
 
Lastly, the analysis of aim three screened for evidence of amplification or deletion 
within the SNP array signal data to determine a set of candidate genes and region of 
interest associated with case/control status. The analysis found inferred regions of 
14q11.2 and 15q11.2 through copy number variation to have some association with 
case/control status. An analysis of association of inferred copy number variation with the 
expression of individual probe sets resulted in a list of candidate genes within these 
regions. Region 14q11.2 found two genes within the region of interest with both being 
from the large olfactory gene family and known to have significant variability.  The 
region of 15q11.2 found 19 candidate genes of interest most specifically genes found to 
be associated with the phenotype of breast cancer and lymphoma and include PAK2, 
CYFIP1, NIPA1, NIPA2, TUBGCP5, BCL8, and numerous hypothetical proteins. 
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CHAPTER 5. DISCUSSION 
 
 
Discussion of Findings 
 
Chapter 5 presents a discussion of the demographic data and the primary aims. 
The findings will be discussed in relation to the conceptual framework along with nursing 
implications and recommendations.  
 
 
Demographic Data 
 
Cases and controls were well matched with no statistical differences in age at HL 
diagnosis and time since diagnosis, maximum dose of mantel/mediastinal radiation, or 
alkylating chemotherapy. Comparison of demographic data for age of menses, 
menopause, and hormonal use found only the age of menopause (p=0.0191) to be 
statistically different between the cases and controls. This difference is most likely due to 
the fact that cases and controls were not matched for para-aortic and/or pelvic radiation. 
For the controls who received pelvic radiation, early age of menopause with onset prior 
to 31 years of age may be most protective against breast cancer [14]. The age at 1
st
 
pregnancy and time of pregnancy after HL have been described as being associated with 
secondary breast cancer [53]; however, these ages were not statistically different between 
the cases and controls. Although not significant, the reproductive history did find that the 
controls had fewer numbers of pregnancies and live births in comparison to the cases. 
This may be related to the earlier menopause secondary to a higher incidence of pelvic 
radiation or other factors that contributed to reproductive decisions. Lastly, the cases and 
controls provided a self report of first and second degree family members with cancer. 
Both the cases and controls reported a 45% incidence of cancer among first and second 
degree relatives with breast being a common cancer among both first and second degree 
relatives.  
 
Breast cancer among the cases was diagnosed on average 36.5 ± 6.7 years of age, 
with a range of 27.2-51 years, which is significantly younger than the general population  
median diagnosis age of 61 years [12]. The time from radiation to the development of 
breast cancer was on average 21.3 ± 5.8 years after radiation and is consistent with the 
previously described range of 15 to 20 years [3, 5, 7]. The controls are approximately 
25.4 ± 6.01 years (range 15.2-33.8 years) from HL diagnosis. This is important in that the 
majority of controls have exceeded the passage of time and the period of highest relative 
risk of secondary breast cancer after radiation exposure. However, there is significant 
variability with a standard deviation ± 6.01 years, meaning that some controls remain at 
an increased relative risk. The cases were also asked specifics regarding their breast 
cancer histology and hormonal markers. Information for the cases and chart review 
revealed no difference between the presentation of those with secondary breast cancer 
and sporadic disease. While bilateral disease has been reported to occur more frequently 
among HL survivors [3], only one case reported a bilateral occurrence. 
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Age at menopause (p=0.0191) was the only significant variable with statistical 
difference between the cases and controls. Overall, the demographic data found these 
survivors of pediatric HL to be a very homogenous group except for the occurrence of 
secondary cancer.  
 
 
Primary Aim One 
 
Aim one sought to determine the global gene expression differences between 
cases and controls. The global gene expression found significant gene expression 
differences in genes that are inter-related within 12 molecular pathways. These 12 
pathways can be grouped into larger pathways of amino acid metabolism, metabolism of 
cofactors and vitamins, biosynthesis of secondary metabolites, and genetic information 
processing including folding, sorting and degradation, translation, and DNA 
replication/repair. The 12 significant pathways are outlined in Table 5.1. Within these 
pathways 43 genes and their isoforms were differently expressed between cases and 
controls with test p-value and permutation p-values of significance. However, the false 
discovery rate for each of the genes was .70 or greater indicating that 70% of the reported 
results are expected to be false discoveries. Although the data declare a high false 
discovery rate, the gene set is of interest in relation to the phenotype of secondary breast 
cancer.  
 
 
Pathways of Significance 
 
Folate-Methionine Pathway.  One carbon metabolism, DNA methylation, synthesis, and 
repair have been long studied as mechanisms for the development of carcinogenesis.  The 
methionine and folate metabolizing pathways are integral for DNA synthesis and 
methylation and are of interest with this study phenotype. During translation and 
transcription, gene expression is associated with the patterns of modification of DNA 
through the process of methylation. The process of methylation is not an alteration in the 
nucleotide sequence, but results from an addition of a methyl group to the cytosine-
phopshoguanine (CpG) promoter region of the gene [84] . These CpG islands are located 
in over half of all human genes [85]. Gene expression can be altered by DNA methylation 
resulting in both hypomethylation and hypermethylation. DNA hypomethylation has been 
correlated with cancer through activation of proto-oncogenes, reactivation of transposable 
elements, and loss of imprinting [86]. Hypermethylation results in gene repression of 
tumor suppressors, chromatin condensation, and loss of DNA repair [87]. Methylation 
has been implicated as an early event in breast cancer, with the activation of oncogenes 
and the suppression of tumor suppressors.  
 
Many of the genes involved in DNA methylation and synthesis were statistically 
significant in their differential expression between cases and controls as described and 
depicted in Figure 5.1. The first described is thymidylate synthetase (TS OR TYMS) 
which binds methylenetetrahydrofolate (5, 10-methylene THF) and serves as a 
hydroxymethyl donor in the conversion of dUMP to dTMP which is critical in DNA  
82 
 
Table 5.1 Grouping of Significant Pathways. 
 
Pathway Function Pathway 
Methionine Metabolism 
Histindine Metabolism 
Phenylalanine, Tyrosine, and Tryptophan 
Biosynthesis 
Amino Acid Metabolism 
Phenylalanine Metabolism 
Metabolism of Other Amino Acids Selenoamino Acid Metabolism 
Nicotinate and Nicotinamide Metabolism 
Metabolism of Cofactors and Vitamins 
One Carbon Folate Pool 
Alkaloid Biosynthesis I Biosynthesis of Secondary Metabolites 
 Tetracycline Biosynthesis 
General Information Processing  
Folding, Sorting, and Degradation Type II Secretion 
Translation Aminoacyl-tRNA biosynthesis 
Replication and Repair DNA Polymerase 
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Figure 5.1 DNA Syntheses and Methylation. Adapted with permission of Wiley-Liss, 
Inc. a subsidiary of John Wiley & Sons, Inc. from Lissowska, et al. Genetic 
polymorphisms in the one-carbon metabolism pathway and breast cancer risk: a 
population-based case-control study and meta-analyses. Int. J. of Cancer. 2007. 120: p 
2697 [122].
Up-regulated in Cases 
Comparison to 
Up-regulated in 
Controls in 
Up-regulated in 
Controls in 
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synthesis and was expressed higher among the controls. Another gene, dCMP deaminase 
(DCTD) within the Type II secretion system pathway catalyzes the deamination of dCMP  
to DUMP a substrate for thymidylate syntase and was expressed higher among the 
controls. Inter-related is the process of DNA methylation in which  
methylenetetrahydrofolate reductase (MTHFR) catalyzes the reduction of 5, 10 
methylenetetrahydrofolate (methylene THF) to 5-methyl THF, 5-methyl THF is the 
circulating form of folate and carbon donor for the remethylation of homocysteine to 
methionine. Therefore, MTHFR is important in homocysteine metabolism, methionine 
synthesis and methylation reactions. Reduced gene activity may result in accumulation of 
5, 10 methylene THF and reduced 5-methyl THF. Although not statistically significant, 
controls were found to have a higher expression of MTHFR than the cases. From the 
methionine, methionine adenosyltransferase (MAT2B) catalyzes the biosysnthesis of S-
adenosylmethionine (SAM) and was expressed higher among the cases.  
 
Two vitamin B dependent enzymes were expressed differently between cases and 
controls. Methionine synthase (MTR) is a vitamin B-12 dependent enzyme and catalyzes 
the methyl base from 5-methyl THF to homocysteine for the production of methionine 
and tetrahydrofolate. MTR is also important in maintaining S-adenosylmethionine (SAM) 
for DNA methylation and preventing increased homocysteine and was significantly 
expressed higher among the controls. Vitamin B6 enzyme, serine 
hydroxymethyltransferase (SHMT) was found to be expressed higher in the cases than 
controls. SHMT is responsible for conversion of serine and THF to glycine and 
methylene THF and is important in providing one-carbon units for purine, thymidylate,  
and methionine synthesis. Lastly, within Figure 5.1 is dihydrofolate reductase (DHFR) 
which was expressed higher among controls. This gene is within the one carbon folate 
pathway and required for de novo synthesis of amino acids.  
 
Lastly, two genes of importance within the methionine metabolism were tRNA 
aspartic acid methyl-transferase (TRDMT1) expressed higher in the cases and DNA 
methyltransferase 3 alpha (DMT3A) expressed higher in the controls. Both of the 
these genes regulate CpG methylation. The DNMTs transfer a methyl group from SAM 
to generate methylation and the silencing of genes [88]. DNMT3a is a de novo 
methyltransferase and functions to methylate unmethylated DNA.  
 
Dietary intake has been linked with DNA methylation and most specifically 
deficiencies in folic acid, methionine, zinc, selenium have been implicated [89]. While 
the nutritional data remains controversial, there is the link of 5-methylenetetrahydrofolate 
as the precursor of the methyl group needed for methionine to SAM [90]. While adequate 
nutrients are needed, excess of intake of folic acid, methionine, and selenium have been 
known to disrupt DNA methylation [87]. There are many factors that are important in 
maintenance of the folate-methionine pathway with gene expression being differently 
expressed between the cases and controls.  
 
t-RNA-Depedendent Amino Acid Biosynthesis.  The aminoacyl-tRNAs are essential 
substrates in the process of translation and protein synthesis. As ribosome moves along 
the mRNA aligning the codons, aminoacylated-tRNA is brought into line for the transfer 
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from the mRNA into the growing amino acid polypeptide chain. Each aminoacyl-tRNA 
synthetase recognizes its specific amino acid. Therefore, the aminoacylated t-RNA is 
essential in genetic coding and serves a major function as RNA editors. Most of the 
aminoacyl-tRNAs can distinguish their corresponding amino acid; however, many can 
not bringing in the importance of pre and post transfer editing [91]. Mutations within 
aminoacylated t-RNA result in ambiguity of the genetic code and missense substitutions.      
 
Among the cases and controls, the t-RNA depedendent amino acid biosynthesis 
pathway was statistically significant. Eight aminoacyl-tRNA associated genes were 
differentially expressed and all were significantly expressed higher among controls than 
cases. These genes included: three isoforms of MARS which is a methionine tRNA 
synthetase and MARS2 which is the tRNA synthetase responsible for mitochondrial 
tRNA, YARS tyrosyl  tRNA synthase FARS2 phenylalanine tRNA synthetase 
mitochondrial, AARS alanyl tRNA synthase, LARS and LARS2 leucyl tRNA synthase, 
and HARS histidyl tRNA synthase. It could be inferred that lower gene expression 
among cases may be responsible for impaired protein synthesis.   
 
Nicotinate and Nicotinamide Metabolism. The metabolism of nicotinate and nicotinamide 
are pathways of interest due to their response to cellular stress for which four genes were 
expressed higher among the cases than controls. Two isoforms of nicotinamide 
nucleotide adenylyltransferase 2 (NMNAT2) a family of enzymes which catalyze an 
important step in nicotinamide adenine dinucleotide (NAD) biosynthesis were 
differentially expressed. Another gene pre-B-cell colony enhancing factor 1 (PBEF1) was 
also expressed higher among the cases and is involved in the biosynthesis of NAD. The 
biosynthesis of NAD is of interest within cases in that DNA damage is found to stimulate 
NAD biosynthesis and recovery of damage occurs sooner with higher levels of NAD 
[92].  
 
DNA Polymerase. DNA polymerases are important in the repair of DNA after toxic 
exposure and prevent mutagenic lesions within the DNA. Many DNA polymerases are 
known and three were differently expressed higher among the controls than cases and 
include Poly beta sigma and gamma. Poly beta supports DNA maintenance, replication, 
and recombination through base excision repair. Poly beta has been found to be involved 
in DNA repair of UV lesions allowing DNA to repair through translesion synthesis[93]. 
In tumor formation, an  increased expression of Poly beta is consistent with synthesis of 
genes needed for DNA repair in an attempt to detain the mutagenic lesion [ 94, 101]. 
 
Biosynthesis of Secondary Metabolites. Another gene of interest and associated with 
breast cancer is Acetyl-CoA carboxylase ? which was expressed higher among the 
controls. This gene has been identified as being a partner of the breast cancer gene 
BRCA1 and interacts with AAC ? via the tandem of BRCT domains in BRCA1 [94]. 
Therefore, the higher expression among the controls may facilitate the interaction and 
function of BRCA1. This gene has been found to be expressed in the liver, adipose, brain 
and mammary gland during lactation. AAC ? is highly expressed in breast carcinoma 
[94]. 
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Global Gene Expression Summary 
 
The study finds that there are differences in the global gene expression between 
those with and without secondary breast cancer. The expression data defines 12 
molecular pathways and 43 genes (p ? 0.05) differentially expressed between the cases 
and controls within each of the pathways. Most specifically, the cases were found to have 
lower expression in the folate-. methionine,  t-RNA-Depedendent Amino Acid 
Biosynthesis,  Nicotinate and Nicotinamide Metabolism. Regardless of the direction of 
change in gene expression, differences were found between the cases and controls and 
occurred within key processes of amino acid metabolism, one-carbon metabolism, DNA 
replication, and RNA translation.  
 
These pathways of interest are very similar to those described by the consensus 
coding sequences of human breast and colon cancer [95]. This study evaluated genetic 
mutations of tumors, focusing on protein coding genes or consensus coding sequences. 
This data generated a list of somatic mutations and candidate cancer genes. Each of these 
genes was assigned a function based on molecular function or biochemical processes. For 
breast cancer 18% of the genes were transcriptional regulators, of particular zinc finger 
transcription factors. Additional pathways included cellular adhesion and motility, signal 
transduction, transport, cellular metabolism, intracellular trafficking, and RNA 
metabolism, and response to DNA damage stimulus [95]. Many of the described 
pathways within the tumor from the consensus coding sequences were found from this 
study of germline gene expression. Therefore, differential expression within these 
pathways may be important in the transformation of the breast cancer phenotype in cases. 
 
 
Primary Aim Two 
 
Aim two determined the genotype differences between the cases and controls, and 
found there to be SNP’s of statistical significance in allele frequency between the cases 
and controls. As previously discussed, the most significant SNP’s with a chi-square p-
value < 0.001 were transformed, plotted, and highlighted according to the chromosome 
location. A Geneset enrichment p-value file was created to determine the genes 
associated with the SNP’s of interest and found 574 genes associated with the 
corresponding SNP. SNP’s of greatest significance and within clusters were determined 
to be of highest interest and were found on chromosomes 5, 10, and 11. These SNP’s are 
described according to their corresponding gene function and relevance to the phenotype 
of breast cancer.  
 
 
Differences in Genotype 
 
            As previously described, chromosome 5 displays a significant SNP_1907286  
(-log 10 p= 4.8) at position 31786818. This SNP is associated with the PDZD2 gene and 
is found in an intron and falls within the outer boundaries of the transcript record [29]. 
The PDZD2 has a physical position of 31834787-32146794; therefore, the SNP is not 
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located within the gene thus a Geneset enrichment value of (p=0.49; FDR?1). Next the 
known allele frequency was considered. The SNP allele A/T frequency among CEPH 
(Utah residents with ancestry from northern and western Europe) found the major A 
allele at a 38% occurrence, minor T allele at a 62% occurrence, and a heterozygoisty 
frequency of 47% [29]. Therefore, this is a commonly occurring polymorphism among 
the CEPH population studies. The SNP associated gene, PDZD2 has been noted to be 
associated with prostate tumors but no association with breast cancer. The PDZD2 gene 
contains PDZ domains that have been shown to bind the C-termini of transmembrane 
receptors or ion channels and could be involved in intracellular signaling. The protein 
encoded by this gene contains six PDZ domains and the encoded protein localizes to the 
endoplasmic reticulum and is thought to be cleaved by a caspase to produce a secreted 
peptide containing two PDZ domains. The gene has been found to be unregulated in 
primary prostate tumors [83]. 
 
            The largest cluster of differentially expressed allele frequencies was found on 
chromosome 10, over a region of 6.1 kilobases with 11 differentially expressed SNP’s 
between cases and controls. As previously described, two highly significant SNP’s within 
this region are SNP_A-2181577 (-log 10 p=3.97) and SNP_A-2006464 (-log 10 p=3.97) 
at position 127481155 and 127485797 and statistically associated with the UROS gene 
(p=.001; FDR ?1) located at position 127467141-127501757. Both SNP’s are found in 
the gene intron and fall within the outer boundaries of the transcript record [29]. SNP_A-
2181577, allele C/T among the CEPH population has a major allele frequency of 61%, 
minor allele frequency of 38.6% and a heterozygosity frequency of 47.4%. SNP_A-
2006464, allele A/C among the CEPH population has a major allele frequency of 59%, 
minor allele frequency of 41% and a heterozygosity frequency of 48% [29]. The UROS 
(uroporphyrinogen II synthase) gene encodes a gene which catalyzes the fourth step of 
porphyrin biosynthesis in the heme biosynthetic pathway and is found to have no 
correlation with the phenotype of breast cancer [83].  
 
            SNP_A-1842005 (-log 10 p= 3.98) at position 127508528 was found to be the 
most significant SNP within the region of chromosome 10 and was statistically associated 
with the BCCIP gene (p=.001; FDR ?1) located at the physical position of 127502104-
127532080. SNP_A-1842005, allele C/T among the CEPH population has a major allele 
frequency of 59%, minor allele frequency of 40%, and a heterozygosity frequency of 
48% [29]. The BCCIP gene is a BRCA2 and CDKNIA interacting protein and was 
isolated due to its interaction with BRCA2 and p21 proteins. It is an evolutionarily 
conserved nuclear protein with multiple interacting domains. Functional studies indicate 
that this protein may be an important cofactor for BRCA2 in tumor suppression, and a 
modulator of CDK2 kinase activity via p21. Several transcript variants encoding different 
isoforms have been described for this gene [83].  This gene may prove to be very 
important within this cohort due to the BCCIP gene interaction with BRCA2 and 
association with breast cancer phenotype. 
 
             The BCCIP gene is of interest due to its interaction with the tumor suppressor 
BRCA2 and association with the phenotype of breast cancer. The function of BCCIP was 
first described due to its interaction with BCRA2 and CDKN1A (p21) [96]. BRCA2 is 
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known to be a tumor suppressor and is involved in DNA repair contributing to genomic 
stability [97], regulation of mitosis and cytokinesis ensuring numerical chromosomal 
stability [98]. Lu et al [99] described the chromatin-bound fraction of both BCCIP 
isoforms colocalize with BRCA2 and contribute to BRCA2 and RAD51 nuclear focus 
formation. A recently published study found that downregulation of either BCCIP 
isoform significantly reduces DNA double strand break-induced homologous 
recombination, impaired G1/S checkpoint activation, abrogates p53 transactivation and 
down-regulates p21 expression [100, 101]. Therefore, BCCIP expression may regulate 
genomic stability through multiple pathways including homologous recombination repair, 
S checkpoint, and cytokinesis. Additionally, BCCIP may regulate centrosome stability 
through p53 and p21 function, sequestering p53 protein from the p21 promoter despite an 
elevated total p53 protein level [101]. Due to the importance in genomic stability, BCCIP 
loss may lead to tumorgenesis and becomes an important candidate gene for the 
phenotype of breast cancer.  
             
            Within this polymorphic region there were two other significant regions of allele 
frequency differences between cases and controls, SNP_A-1944367 (-log 10 p= 3.55) 
located at position 127555310 and SNP_A-1887998 (-log 10 p= 3.47) located at position 
127455338.  SNP_A-1944367 is located within the intron of the gene DHX32 (p=.001: 
FDR ?1) and falls within the boundaries of the transcript record. The allele C/T among 
the CEPH population has a major allele frequency of 40%, minor allele frequency of 
60%, and heterozygosity frequency of 48% [29].  The gene  DHX32 (Dead box 
polypeptide 32) is characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD) 
which are putative RNA helicases. They are implicated in a number of cellular processes 
involving alteration of RNA secondary structure such as translation initiation, nuclear and 
mitochondrial splicing, and ribosome assembly and may be involved in cellular growth 
and division.   
 
            The DHX32 gene is of interest due to its role in RNA metabolism which was 
found to be a significant pathway within the analysis of global gene expression. DHX32 
gene expression has been found to be down-regulated in acute lymphoblastic leukemia, 
lymphoblastic lymphoma, and follicular lymphoma. Inversely the DHX32 has been found 
to be up-regulated in mantle cell lymphoma, B-cell lymphoma, and Reed Sternberg cells 
in cases of nodular sclerosis Hodgkin lymphoma have been found to strongly express 
DHX32 [102, 103]. Not only has the DHX32 gene expression been association with 
Hodgkin lymphoma, DHX32 is an anti-sense to the BCCIP gene. The last three exons of 
the BCCIP gene overlap the 3'-terminal seven exons of the DHX32 gene [102]. 
 
           The second SNP of significance within this region, SNP_A-1887998 is located 
downstream 11800 bases from the transcript of the gene UROS and 958 bases upstream 
from the transcript of the gene MMP21 (p=.001: FDR ?1). The allele C/T among the 
CEPH population has a major allele frequency of 69%, minor allele frequency of 30% 
and heterozygosity frequency of 42%. The MMP21 gene (matrix metallopeptidase 21) 
encodes a member of the matrix metalloproteinase family involved in the breakdown of 
extracellular matrix for both normal physiological processes, such as embryonic 
development, reproduction, and tissue remodeling,and disease processes, such as asthma 
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and metastasis [82]. The MMP21 gene has been found to contribute to tumor 
development and polymorphisms within this gene have been associated with an increased 
risk of cancer [104, 105].  
 
          The analysis found the most significant SNPs, SNP_A-2294376 (-log 10 p=5.1) 
and SNP_A-2209464 (-log 10 p=5.2), to be located on chromosome 11 at position 
119148037 and 119149661 and are associated with the genes TRIM29 and PVRL.  
SNP_A-2294376 is located upstream at a distance of 43392 nucleotide bases from the 
transcript of PVRL1 and downstream 339168 nucleotide bases from the transcript of 
TRIM29. SNP_A-2209464 is located upstream at 45016 nucleotide bases from the 
transcript of PVRL1 and downstream 337544 nucleotide bases from the transcript of 
TRIM29. Due to the SNP location in relation to the gene, these genes were not 
statistically associated with the SNP in the Geneset enrichment file, TRIM29 (p=0.845) 
and PVRL (p=0.142).  
 
 
Genotype Summary 
 
Aim two found that there were differences in the genotype of those with and with 
out breast cancer and the most significant genotype differences were found on 
chromosomes 5, 10, and 11. A region within chromosome 10 was found to have the 
largest cluster of significant genotype variability and genes that are of importance to the 
breast cancer phenotype. From this analysis, SNP’s within the BCCIP and DHX32 gene 
were found to statistically significant, overlap in physical position, and have been 
described as being associated with the phenotype of breast cancer and Hodgkin 
lymphoma. Additionally, polymorphisms within the gene MMP21 as described have been 
associated with an increased cancer risk. The region within chromosome 10 becomes is 
of importance for further validation and analysis due to the strong association with the 
phenotype not only of breast cancer but of Hodgkin lymphoma.  
  
 
Primary Aim Three 
 
 
Copy Number Variation 
 
Aim three identified inferred regions of 14q11.2 and 15q11.2 through copy 
number variation to have some association with case/control status. It is known that copy 
number variation is integral in the genomic variation between individuals. However, the 
extent to which genetic variability contributes to disease is unknown. One study suggests 
that copy number variations greater than 100 kilobases contribute to genetic variation and 
found these large scale variations to differ by 11 copy number polymorphisms with an 
average length of 465 kilobases [106]. Nozawa et al [107] found that 14.2% of the human 
gene loci have copy number polymorphisms. Therefore, regions of copy number 
variation are not uncommon but will vary according to those sampled. Although the 
effect of copy number variation on the phenotype is unknown, it is thought that the effect 
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is significant given the impact of copy number variation on gene expression [108]. Copy 
number variation requires additional analysis of the genotype data. This can be explained 
in that the SNP genotype assumes 2 copies and will force variants to conform to the chip. 
For example, the region of copy number variation amplification may have a genotype of 
AAB, which will be recorded as AA or AB on the SNP chip without inference to the 
additional allele. Therefore, this study analyzed the genotype data for areas of copy 
number variation. This analysis found regions of copy number variation at 14q11.2 
(p=0.069) and region 15q11.2 (p=0.067). From the copy number polymorphisms the log-
transformed Affymetric U133 plus expression signal by inferred copy number status for 
each of two probe sets mapped to genes that overlap or are located with 5,000 base pairs 
of the copy number variation region. This provided the candidate genes for the two 
regions of interest. 
 
The region of 14q11.2 was mapped to two genes OR4N4 and OR4Q3. These 
genes are olfactory sensory genes and one of the largest gene families with the genome. 
The sensory genes have been studied due to their large number of copy number variations 
[109, 110]. It is thought that this variation is the result of physiological requirements in 
response to ones environment [107]. In addition, the sensory gene families are thought to 
contain a large number of pseudo genes [103, 104] that appear to have experienced 
random change in copy number variation and have undergone genetic drift [111]. This 
region of variation is well documented and most related to evolutionary change.  
 
The region of chromosome 15q11-13 has been found to be one of the most 
unstable regions within the genome [112]. Clinical cytogenetic analysis have frequently 
identified a region of amplification on 15q that has not been associated with Prader-
Willi/Angleman Syndrome and appears to have no significant effect on phenotype [113, 
114]. This region of amplification has also been studied for patterns of inheritance and 
found inherited from either sex parent with no apparent parent of origin effect [115]. 
Another study followed 130 families with unbalanced chromosome abnormalities at five 
regions including 15q11-13 and 70 families with euchromatic variants including 15q11.2 
[116]. Among the families with an unbalanced chromosome abnormality, 9 families had a 
duplication of this region with either an affected child or an affected parent and child. 
Expression of phenotype was due to involvement of the critical Prader-Willi region and 
included developmental delay and autism. Thirty two families were found to have 
euchromatic variants within the region of 15q11.2. Euchromatic variants reflect copy 
number variation of segements of genes and pseudogenes which are polymorphic in the 
general population and typically have no phenotypic effect. This study found 32 families 
to have duplications within 15q11.2. This gain in copy number is thought to be the result 
of additional copies of the NF1 pseudogene. Additionally, the study notes that similar 
variation my be expected at other sites of the NF1 pseudogene including 14q11.2 [116]. 
Another study has also documented the 15q duplication has being inherited from either 
parent with no effect on phenotype, and related to the polymorphic regions of pseudogene 
sequences [115]. Within this analysis of copy number variation, 11 controls were found 
to have duplication at 15q11.2; no case was found with duplication. From the described 
studies and this duplication only occurring within the controls, it is likely a common 
inherited variant with no effect on phenotype.  
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 The occurrence of deletion was found in 4 cases and 9 controls, including the one 
case who has died from breast cancer progression and a control who has died from 
another secondary tumor. Deletion within this region has typically been described with 
Prader-Willi and Angleman Syndrome. A search of the literature found no reports of a 
deletion at this region in association with the phenotype of breast cancer or Hodgkin 
lymphoma. However, the analysis of family history as described earlier did find an 
association (p=0.039) with the deletion and first degree relative with breast cancer for 
both the cases and controls.  
 
The remainder of the cases and controls had no change within this region. 
However, in reviewing the data it is important to keep in mind that this analysis compares 
signal values from within the cohort to themselves. Therefore, it is most likely that many 
of the copy number variations were missed. It is likely that many of those found in the 
analysis to be no change may actually have a duplication or deletion when the validation 
real-time PCR is complete. It is less likely that those with a duplication or deletion in this 
analysis become no change (two copies). This conclusion is inferred from the ad hoc 
statistical approach.  
 
The location of the copy number variations produced a list of candidate genes for 
the 15q11.2 region. This list included CYFIP1, PAK2, RNF145, NIPA1, NIPA2, BCL8, 
TUBGCP5, and numerous hypothetical proteins. Expression of these genes was not noted 
to be directional according to copy number variation.  A review of the literature explored 
the association of these candidate genes with the phenotype of lymphoma, cancer, and 
breast cancer.  
 
The region of 15q11-13 has been found to be a site of rearrangements in 3-4% of 
those diagnosed with diffuse cell large cell lymphoma and is the location of BCL8 a B-
cell lymphoma gene [117]. The BCL8 was found due to this recurrent site of 
rearrangements in a small number of large cell lymphoma patients. The function of BCL8 
is not understood but it is ectopically activated in lymphomas. Furthermore, it is 
speculated that this site rearrangement is most likely related to mutations in the 
regulatory region or deregulation by a trans-acting factor or gene deregulation by changes 
in the imprinting pattern of the chromosomal region [117].  
 
Two of the candidate genes, PAK2 and CYFIP1 are within the tyrosine kinase 
family. Tyrosine kinases are enzymes that transfer a phosphate group causing 
phosphorylation after a factor binds to its receptor. This allows the cell to participate in a 
chemical reaction such as activation of a signaling pathway. CYFIP1 is a tyrosine kinase 
which has been found to have differential expression during breast cancer development 
[118]. The serine threonine protein kinase, PAK2 is activated by cellular stress such as 
hyperosmolarity, ionizing radiation, and DNA damage. PAK2 executes part of the 
cellular response to stress by inhibiting activity of Myc and may be a tumor suppressor 
[119]. Expression of PAK2 is frequently affected by rearrangements associated with 
hematological malignancies such as chronic lymphocytic leukemia and B-cell lymphoma. 
The interaction between Myc and PAK2 may be bidirectional, in that Myc may down 
regulate PAK2 [120]. Lastly, candidate genes, NIPA1 and TUBGP5 have recently been 
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documented as having potential implication in the development of breast cancer in Li-
Fraumeni syndrome animal model [121].  
 
 
Copy Number Variation Summary 
 
The copy number analysis found some association with case/control status and 
copy number variation at 14q11.2 and 15q11.2. Amplification with this region in those 
with no phenotype effect has been described as an euchromatic variant and likely related 
to the polymorphic segment of the NF1 pseudogene [115, 116]. However, the deletion is 
not described within the literature and may be of interest with the phenotype of breast 
cancer. This is further warranted with the association noted between the deletion among 
the cases and controls and family history of breast cancer. Lastly, the region of 15q11.2 
provides another list of potential candidate genes that may be associated with the 
development of breast cancer among HL survivors. The genes of greatest interest include 
CYFIP1, PAK2, NIPA2, and TUBGCP5 which have been cited in the literature as being 
associated with the phenotype of breast cancer as previously described. An analysis is 
ongoing to validate the presence of amplification or deletion within the 15q11.2 region of 
interest. 
 
 
Relation of Study Results to Conceptual Framework 
 
This study evaluated the similarities and differences in global gene expression, 
genotype, and copy number variation among females treated for pediatric HL with and 
without the development of secondary breast cancer. The conceptual model (see Figure 
1.1) depicts each individual with treatment related risk factors including age at treatment, 
dose of mediastinal and pelvic radiation, and dose of alkylating agents. There were no 
statistical differences in age, mediastinal radiation, or alkylating agents; however, there 
were differences between the cases and controls receiving pelvic radiation and age of 
menopause. It is these treatment characteristics and their interaction with inherited 
characteristics that place the individual at an increased risk of secondary breast cancer. 
Therefore, the family history was assessed between the cases and controls, with no 
differences noted. However, at the time of therapy the family history is less suggestive of 
potential breast cancer risk and should be reevaluated with the passage of time. 
Additionally, at the time of therapy, the individual’s genetic influences are unknown; 
therefore, the individual’s ability to maintain genomic stability after the initiation of 
radiation and chemotherapy at a young age is unknown. Females who maintain genomic 
stability have ablation of tumor and cellular apoptosis or DNA repair secondary to the 
genomic insult of radiation and chemotherapy. Females who are unable to maintain 
genomic stability will retain mutated lesions and with additional insults over time will 
likely develop secondary breast cancer.  
 
This study found differences in gene expression, genotype, and a region of copy 
number variation among the cases and controls. These findings will require a step wise 
validation with further analysis and subsequent study. If validated these findings could be 
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used as a screening for females at potential risk of secondary breast cancer after HL 
therapy. While these validation studies are on going, changes in the conceptual model 
should include a periodic update of the individual’s family history. Future studies will 
continue to match treatment variable between cases and controls and will include pelvic 
radiation. Lastly, each individual should be made aware of lifestyle characteristics that 
reduce additional genetic insults such as healthy diet (folic acid, methionine, and 
selenium), limited sun exposure, non smoking, use of hormonal therapy and limited 
alcohol intake. For young females undergoing pediatric cancer therapy, their family 
history may not be noted as positive for breast or other cancer. However, these females 
should understand the importance of their family history, lifestyle characteristics and the 
implications these have for their own health risk. There will be an ongoing assessment of 
the conceptual framework in subsequent studies.    
 
 
Nursing Implications 
 
     This study has  implications for nursing research and practice. The knowledge 
gained could provide a larger framework of research in the exploration of the biological 
mechanism underlying early on-set breast cancer after a childhood cancer. With an 
improved understanding of inherent risk factors, the biological mechanism, and the 
interaction of endocrine influences, this finding could assist in developing a predictive 
clinical model. It is reasonable that future treatment approaches may require screening for 
breast cancer-related polymorphisms or copy number variations prior to treatment of 
pediatric HL. If future screening identifies an individual with a genetic predisposition for 
the development of breast cancer, therapy may be modified in an effort to decrease this 
risk. This may include a modification of radiation, chemotherapy, hormonal therapy post-
treatment therapy, or the administration of anti-estrogen therapy. The individual and 
family would be informed of and develop an understanding of potential risk and the 
measures that are needed to heighten surveillance. This surveillance should also entail an 
annual review of the individual’s family cancer history and most specifically that of 
breast cancer among primary and secondary degree relatives. In practice the oncology 
nurse would navigate the individual through a surveillance plan which would include 
monthly self-breast exam, counseling in obtaining a biannual physician breast exam and 
annual diagnostic imaging. The nurse should provide counseling that may reduce 
oxidative stress and genomic insults through lifestyle characteristics such as healthy diet 
(folic acid, methionine, and selenium), limited sun exposure, non smoking, limited use of 
hormonal therapy and limited alcohol intake. Lastly, the nurse can explain and 
disseminate these findings to primary care providers caring for these women.   
 
 
Limitations 
 
The major limitation of this study is the small sample size of 13 cases and 36 
controls. While SJCRH is a large center for patient accrual with secondary breast cancer 
after pediatric HL, only 14 known secondary breast cancer survivors where eligible at the 
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time of patient enrollment. To compensate for the small case sample size, matching of 
three controls did improve the efficiency for binary measures.  
 
Another limitation of the study is the generalizability of the study findings. This 
study was designed to explore the mechanism of secondary breast cancer after pediatric 
HL; therefore, this study can not be generalized to sporadic breast cancer and will need 
further study among those with breast cancer after other pediatric cancers. Cases and 
controls were screened for active disease prior to blood collection; however, both cases 
and controls have subsequently reported disease reoccurrence or newly diagnosed 
disease. Therefore, the gene expression data may be affected by current disease status. 
Lastly, genomic analysis is moving at a rapid pace and provides numerous biostatistical 
and bioinformatical methodological limitations. 
 
 
Recommendations 
 
 
Recommendations for Research 
 
These data and analysis provide a vast number of future hypotheses generating 
questions.  
 
1. The study findings must be validated by real time PCR to determine the  
       presence of candidate polymorphisms and a gain, loss or no change at15q11.2 
        
2. Further analysis of data to determine if variation in gene expression is related  
to genotype or copy number variation. 
 
3. The study should be replicated in females treated for other pediatric cancers  
      who develop secondary breast cancer and all new cases of HL associated  
      breast cancer.  
 
4. The current data should be compared to other genomic data sets that have  
                  evaluated germline polymorphisms among survivors of other pediatric cancers                
                  and females with sporadic breast cancer. 
 
5. Further studies should utilize the DNA repository that was imitated through  
      this study and access other polymorphisms of interest that were not included  
      in the 500K genotyping such as the polymorphism associated with MDM2. 
 
6. Additional analysis of the cases and controls in comparison to other genomic 
data sets to explore genomic etiology that may be associated with pediatric 
HL.  
 
7. If the findings are replicated in associated studies, prospective screening may  
      be appropriate in the diagnostic HL evaluation. 
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Recommendations for Practice 
 
Currently, these study findings will not have application in clinical practice. 
However, if the real time PCR finds the locus of interest to be valid, findings may have 
clinical implications. The study should first be replicated within a larger HL cases/control 
designed study. If the findings are consistent and the loss (deletion) is found to be 
associated with secondary breast cancer, controls that have the deletion will require 
heightened monitoring and breast cancer surveillance. If the locus of interest is validated, 
evaluation may become routine for the newly diagnosed HL patient prior to the initiation 
of therapy.   
 
 
Conclusion 
 
This study was an unbiased genome scan of germline DNA and RNA with unique 
and common loci identified and provides a data base for additional analysis. This study 
explored the global gene expression and genotype between females treated for pediatric 
HL with and without the development of secondary breast cancer. To the best of my 
knowledge, this is the first genome wide association study among female HL survivors 
with and without secondary breast cancer. With the use of two genome wide approaches, 
this study found differences in global gene expression, genotype, and  two regions of 
copy number variation that were associated with case/control status.  The study did find 
that the global gene expression is different among cases and controls with differences in 
amino acid metabolism, translation, and DNA repair giving a list of candidate genes with 
these pathways.  Secondly, the study found that there were differences between cases and 
controls and their genotype expression. Of particular interest are genotype differences 
with the BCCIP and DHX32 genes which have association with the phenotype of breast 
cancer and Hodgkin lymphoma. Lastly, the genotype data were screened for 
amplifications and deletions and found a near significant region of variability. The 
deletion of the region was found to be associated with a first degree family history of 
breast cancer; therefore, these women warrant continued follow-up for the development 
of breast cancer. Lastly a set of genes were described within this region and documented 
within the literature as being associated with the phenotype of breast cancer. This data 
analysis warrants validation of findings and further data analysis in determining potential 
candidate genes and genotypes in association with the development of breast cancer after 
pediatric Hodgkin lymphoma.  
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APPENDIX B. INTRODUCTORY LETTER 
 
 
Date 
Patient’s Address 
 
Dear (Patient’s Name), 
 
We are writing to you and other women who were treated at St. Jude Children’s Research 
Hospital for pediatric Hodgkin disease to ask your participation in a new research study. 
We will describe the study in this letter, and we welcome any questions you may have. 
 
Women who were treated for pediatric Hodgkin disease are at an increased risk for 
development of breast cancer with the greatest risk occurring 15 to 20 years after 
Hodgkin disease. Researchers do not yet understand all the factors associated with 
increasing a women’s risk of breast cancer after Hodgkin disease therapy. We would like 
to learn why some female Hodgkin disease survivors develop breast cancer while other 
female Hodgkin disease survivors do not. We believe that a better understanding may be 
obtained by exploring the genetic differences that affect a woman’s tolerance to radiation 
and chemotherapy. Therefore, we have chosen to conduct a research study that will 
examine and compare the genetic differences between pediatric Hodgkin disease 
survivors who developed breast cancer to those pediatric Hodgkin disease survivors who 
have not developed breast cancer.  
 
We will contact you by phone within two weeks after you receive this letter. During that 
call, we will ask if you would like to participate in this study. If you agree to participate, 
we will ask you to give verbal consent and complete a10 item questionnaire over the 
telephone. The verbal consent and questionnaire conversation will be taped; the tape will 
not begin until you give taping approval. The tape will be in a locked cabinet and can not 
be linked with you. The tape will be destroyed after the completion of the study and 
publication of study findings. We have enclosed the questionnaire for your review.  
 
We will also ask that you read, sign, and return the enclosed consent form. The consent is 
enclosed along with an explanation of this study. Once we have received your signed 
consent, we will ask that a blood sample be obtained at your local physician’s office, a St. 
Jude affiliate clinic, or at St. Jude Children’s Research Hospital. We will pay for the cost 
of the blood sample. 
 
Please know that you do not need to take part in this study-it is voluntary. Please feel free 
to contact either of us at the hospital with any questions about this study (901) 495-4209. 
We would be glad to have the opportunity to discuss it with you. Our very best to you 
always. 
 
Belinda Mandrell, PhD candidate, RN 
Melissa Hudson, MD   
RESEARCH PARTICIPANT STATEMENT 
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APPENDIX C. INFORMED CONSENT STATEMENT 
 
 
THE MOLECULAR PROFILE OF WOMEN WITH AND WITHOUT 
SECONDARY BREAST CANCER AFTER TREATMENT OF PEDIATRIC 
HODGKIN DISEASE 
 
You are being asked to take part in a research study because you were treated for 
pediatric Hodgkin disease. This study will help researchers understand more about why 
some women treated for Hodgkin disease develop treatment-related breast cancer while 
other women do not. This study is not testing for a genetic or inherited disease (passed on 
in families) but is looking at genetic differences that may help explain how the body 
responds to radiation and chemotherapy. This research approach may help identify risk 
factors for secondary breast cancer at the time of Hodgkin disease diagnosis. If so, that 
information could be used to adjust Hodgkin therapy.   
 
This consent form gives you information about the study, which will be discussed with you.  Once you 
understand the study, and if you agree to take part, you will be asked to sign this consent form.  You will be 
given a copy of the consent form to keep. 
 
Before you learn about the study, it is important that you know the following: 
 
• Whether or not you take part in this study is entirely up to you. 
• You may decide not to be in the study, or to withdraw from the study at any time. 
• This study is being sponsored by the American Cancer Society, National Institutes of 
Health, and St. Jude Children’s Research Hospital.   The sponsors will receive 
anonymous information about your treatment characteristics as related to the study.  
 
 
Why is this study being done? 
 
We now know that after treatment for pediatric Hodgkin disease, patients can have 
problems with late effects from Hodgkin therapy. For women treated for pediatric 
Hodgkin disease, the risk of developing breast cancer is higher than among the general 
population. Doctors caring for Hodgkin disease survivors are not sure why some women 
develop breast cancer and others do not. The purpose of this research study is to compare 
genes in women treated for pediatric Hodgkin disease who develop breast cancer to the 
genes of women treated for pediatric Hodgkin disease who did not develop breast cance 
 
The study has the following primary goals: 
 
1. To assess for a difference in the RNA (gene appearance) of women who received chest    
radiation for pediatric Hodgkin disease and later developed breast cancer or did not. 
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2. To assess for a difference in the DNA of women who received chest radiation for 
pediatric Hodgkin disease who later developed breast cancer with the DNA of those 
women who did not develop breast cancer.  
 
3. To assess if genes may be identified through the study of RNA and DNA that may 
represent a women’s higher risk of developing breast cancer after Hodgkin disease 
therapy. 
 
The study has the following secondary goal: 
 
1. To assess for any association between the use of hormones, childbirth, and family 
history and the development of secondary breast cancer. 
 
How many research participants will take part in the study? 
 
Forty eight (48) women treated at St. Jude Children’s Research Hospital, from 1970-
1991, for pediatric Hodgkin disease who subsequently did or did not develop breast 
cancer will be asked to participate in the research study.  
 
What is involved in this study? 
 
As a survivor of pediatric Hodgkin disease you are invited to participate in this study. 
This research study has two parts: 
1). A telephone interview asking questions about  
a) your use of hormones for birth control, fertility or ovarian failure 
b) pregnancies 
c) family cancer history  
2). Collection of a blood sample.  
 
You will be ask to join this study only after you have been fully informed by way of the 
enclosed letter and telephone conversation with the primary researcher, your questions 
have been answered, and you have verbalized an understanding of the study. After 
obtaining your verbal consent during the phone conversation, you will be asked to 
respond to 10 questions regarding your use of hormones for birth control, ovarian failure, 
or fertility. You will also be asked your history/date of pregnancies and your family 
history of cancer. You will also need to give your written consent using the attached 
consent forms. These forms will need to be returned to St. Jude in the enclosed envelope. 
You will also be instructed on blood collection. The blood collection will require 11 mls 
(2 teaspoons) of blood. This blood may be collected at St. Jude, an affiliate clinic, or at 
your local doctor’s office. All supplies and instructions will be forwarded to your doctor 
and the blood will be returned to St. Jude by express mail.  Participants will only be 
enrolled once in this study. All samples will be mailed via Federal Express to the 
RNA/DNA extraction lab of Dr. Mary Relling, St. Jude Children’s Research Hospital, 
332 North Lauderdale, Memphis, TN  38105. You will not pay for any of these costs. All 
costs will be paid from a grant at St. Jude. The consent process will be documented in the  
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medical record as per institutional guidelines. We also ask you to allow us to save any 
left over DNA not used in this study. We seek your permission to store the left over DNA 
for potential future research questions regarding pediatric Hodgkin disease and breast 
cancer. This DNA will not be stored with your name and will only be identified by an 
assigned number. Your DNA will be used only for research and will not be sold.  
 
How long will I be in the study? 
 
Once you have submitted the blood, you will be considered off study. You will receive a 
follow-up letter after the study is completed with an abstract of the study, in which 
findings from the study will be described. If you have further questions after reading 
these findings, you may call the primary research investigator, Belinda Mandrell at (901) 
495-4209. 
 
What research studies will be done?   
 
DNA and RNA will be extracted from your blood. The DNA will be analyzed looking for 
common differences between participants with a technique called Single Nucleotide 
Polymorphisms (SNPs). The RNA will be analyzed looking at differences in gene 
expression using a technique, microarray analysis. This is not a diagnostic technique and 
is a research analysis only. 
 
What will I learn about the results of this study? 
 
Your individual test results are not linked to your personal information, and are 
unavailable to the investigators, we are unable to report them back to you. 
 
What are the risks of the study? 
 
The researchers in this study will protect your records and blood sample and insure that 
your samples will be labeled without your name and will not be directly linked to you. 
The results of this research will not be added to your St. Jude record.  
 
The risk from blood collection will be related to having a needle put into a vein which 
may cause a feeling of faintness, pain, bruising, and a minimal chance of infection. 
 
What are the benefits of this study? 
 
This research approach may help identify risk factors for breast cancer at the time of 
Hodgkin disease diagnosis and could result in adjustment of Hodgkin therapy.  The future 
benefit of participation in this study is for others who will be learning more about what 
causes cancer, how to prevent second cancers, and how to offer better treatment. This 
research may help children with Hodgkin disease in the future.  
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What are the consequences of not joining the study? 
 
You can choose to not join or to stop participating in the study at any time. Your 
participation is voluntary. The alternative to participating in this study is not to 
participate. You may contact us anytime at (901) 495-4209 and tell us you do not want  
 
your information or blood used for this study. Your information and your blood specimen 
will be discarded and no longer used for research.  
 
Compensation 
 
There is no cost to participate in this study. There is no payment for participation. 
 
Confidentiality 
 
Your medical records will be kept confidential to the degree allowed by law.  Information 
from your medical records will not be given to anyone outside the hospital unless you 
agree. You will not be identified in any publication about this study. 
 
Government agencies oversee research studies involving people.  Your medical records 
may be reviewed by such agencies if you take part in this research study.  These agencies 
may include the Food and Drug Administration (FDA) and the National Cancer Institute 
(NCI).  Anonymous information regarding your treatment characteristics and the study 
results may also be shared with researchers from other institutions that are involved in 
this study.  These include the American Cancer Society and the National Institutes of 
Health.  By signing this consent form, you are allowing your medical records to be 
reviewed by these persons. 
It may be necessary to check parts of your medical record to be sure that your original 
treatment for Hodgkin disease is recorded correctly and completely.  Such a check might 
be done by the following groups: 
1. A federal agency such as the Food and Drug Administration (FDA) or the National 
Cancer Institute (NCI). 
2. St. Jude Children’s Research Hospital Institutional Review Board, a committee that 
reviews the ethics of research studies. 
3. American Cancer Society 
 
No information other than what is needed for the study is recorded.  Every effort is made 
to protect your privacy. 
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APPENDIX D. SUMMARY OF RESEARCH AND PRIVACY RIGHTS 
 
 
Non-Therapeutic Research 
IRB version:  November 4, 2003  
I have been told the following information:  
1. I may talk as much as I want to with the doctors who are responsible for my care 
about the reasons for this study and about its risks.   
2. This study may have risks that the researchers do not know about now. 
3. There will be no additional costs to me from taking part in this research study.  It is 
the policy of St. Jude Children’s Research Hospital not to bill research participants or 
their families for the cost of medical care.  This includes any costs associated with 
taking part in research studies.   
4. I and my family will not receive any compensation or payment of any kind for being 
in this study, or for any treatments, products, or any other things of value that may 
result from this study.  
5. The hospital policy is not to provide payment if I am injured or damaged by being in 
this study 
6. I have been told that I can withdraw from this study at any time.  
7. I received a copy of the St. Jude Notice of Privacy Practices at the time of 
registration.  That document tells me how my medical information may be used or 
disclosed (given to someone outside the hospital).  I have been told I have the right to 
review the Notice of Privacy Practices before I sign this form.  I have been told that I 
may request another copy of the Notice of Privacy Practices and that it is posted in 
the Hospital and on our website (www.stjude.org). 
8. I have the right to inspect, copy and/or amend (change) my protected health 
information that is to be used or disclosed.  I have been told in this consent form 
about any limitations to this right, such as research information that I will not have 
access to until the end of the study or that will be used strictly for research purposes. 
9. My protected health information will be disclosed to or used by the following: 
 • Investigators and co-investigators of research study  
 • American Cancer Society 
•  National Institutes of Health        
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10. My records may also be reviewed by agencies such as the Food and Drug 
Administration or the National Institutes of Health, or other agencies as required by 
state or federal regulations. 
11. Information about me that may be disclosed includes the following: 
• Complete medical record including information regarding diagnosis, illness, 
treatment, and information that may be recorded about previous diagnosis or 
treatment.   
• Information gathered as a part of this research study as explained in the informed 
consent/authorization. 
12. I have been told that once my records are disclosed to or used by others, St. Jude 
Children's Research Hospital cannot guarantee that information will not be further 
disclosed.  Also, the released information may no longer be protected by federal 
privacy regulations. 
13. I have been told that this authorization for the use and disclosure of my protected 
health information does not expire. 
14. I have been told that I may withdraw my authorization for the disclosure or use of my 
records at anytime, for any reason, with the following exceptions: 
• When that information has already been disclosed or used based on my 
permission 
• When the information is required to maintain the integrity of the study 
 
15. To withdraw my authorization, I must complete a Revocation of Release of 
Authorization form.  I have been told I may request this form at St. Jude Children's 
Research Hospital by calling the Privacy Officer at 901-495-2341.  The form must be 
returned by mail or hand delivery to: 
 
HIPAA Privacy Officer 
St. Jude Children's Research Hospital 
332 N. Lauderdale 
Memphis, TN  38105 
16. I know that if I have more questions about this study or about any injury from the 
treatment, I can call the Principal Investigator of this study, Belinda Mandrell at 
901/495-3300. 
17. I know that I can get more information about my rights as a research participant by 
calling the Chairman of the Institutional Review Board at 901/495-4357 or the 
Research Participant Advocate (Ombudsman) at 495-4644.  If I am outside of the 
Memphis area, I may call 1-866-583-3472 (1-866-JUDE IRB).  This is a toll-free call. 
18. I will receive a copy of this signed statement. 
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19. I have asked to allow the principal investigator to store any left over DNA for 
potential future research questions regarding pediatric Hodgkin disease and/or breast 
cancer. The DNA will not be stored with my name and will be identified by an 
assigned number 
_/_______ I agree to have my DNA stored for potential future research 
_/_______ I do not agree to have my DNA stored for potential future research 
 
PLEASE FAX WITH CONSENT SIGNATURE PAGE TO PROTOCOL OFFICE #6265 
 
I have read (or have had read to me) the contents of this document and have been 
encouraged to ask questions.  I have received answers to my questions.  I give consent to 
take part in this research study and authorize the disclosure and use of my protected 
health information for the purposes of that research. 
 
 
______________________________ ________________ _______________  
Research Participant   Date   Time (AM/PM) 
   
 
 
PHYSICIAN/INVESTIGATOR/DESIGNEE STATEMENT 
 
I hereby certify that I have discussed the research project with the research participant.  I 
have explained all the information contained in the informed consent document, 
including any risks that may be reasonably expected to occur.  I further certify that the 
research participant was encouraged to ask questions and that all questions were 
answered. 
 
 
______________________________ ________________ _______________  
Physician/Investigator/Designee  Date   Time (AM/PM) 
  
 
 
 
 
In case of questions or emergencies in reference to this protocol, please contact: 
St. Jude Children's Research Hospital 
332 North Lauderdale 
Memphis, TN  38105 
(901) 495-3300 - FAX Interdepartmental #6265 
PLEASE FAX CONSENT FORM TO PROTOCOL OFFICE #6265 
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APPENDIX E. DEMOGRAPHIC QUESTIONNAIRE OF HODGKIN DISEASE 
SURVIVORS 
 
 
1. Do you have menstrual periods?   Yes          No 
 
2. What was your age at your first period? ___________________________________ 
 
3. What was your age at your last period or menopause?________________________  
 
4. Have you used hormone (estrogen/progesterone) medication for birth control, to stop   
    bleeding, to regulate your periods, or help with symptoms of menopause?  Yes   No 
 
    If yes, give date or age of starting hormone use and reason of use ________________    
    ____________________________________________________________________ 
    Are you currently on hormone medication?    Yes        No   
If yes, give name of current hormone medication_____________________________ 
    If no, Please give the general date for starting and stopping hormone medication 
    Started___________________________ 
    Stopped__________________________ 
     
5. Have you ever been pregnant?    
    Number of pregnancies __________,   Number of live births________ 
 
      Date(s)of Birth                                        Did You Breast Feed, if yes how long 
   1. 
   2. 
   3. 
   4. 
 
 
 
  6. Please describe your family history of cancer, give blood relative (grandmother, 
grandfather, mother, father, aunt, uncle, sister, brother, children). Also note if the relative 
is from your mother’s (maternal) or father’s (paternal) side of the family.  
 
Relative                Type of Cancer        Age at Cancer Diagnosis        Living or Deceased 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
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 7. Have you had a breast exam by a doctor within the last year?    Yes      No 
 
 8. Have you had a mammogram within the last year?   Yes      No 
 
9. Have you been diagnosed with any other cancers since treatment of pediatric Hodgkin  
    Disease?   Yes         No 
 
    If yes, list cancer _________________________ 
 
10. Please answer if you have been diagnosed with breast cancer after Hodgkin Disease 
treatment. 
 
a. What was the breast cancer histology? 
    Adenocarcinoma       Infiltrating Ductal Carcinoma 
     ?Ductal In-Situ Carcinoma            Other    Not sure 
 
b. Location of breast cancer:  Right Breast            Left Breast         Both Breasts  
 
c. Was the breast cancer positive for any or all of the following? 
Estrogen                  Progesterone                HER-2  Dont’ know 
 
d. What was your treatment for breast cancer (check all that apply to you) 
Surgery       Chemotherapy    Radiation     Hormone Therapy     Other 
 
e. Last date of breast cancer treatment____________________________ 
 
f. Are you currently on hormone therapy for breast cancer prevention or treatment? 
  Yes     No                   
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APPENDIX F. SINGLE NUCLEOTIDE POLYMORPHIMS OF INTEREST 
 
 
probeid test.stat test.p perm.p q Probe.Set.ID 
Gene 
Symbol 
Chromosomal. 
Location 
219812_at 3.985615 6.73E-05 1.00E-04 0.6786 219812_at MGC2463 chr7q22.1 
1559777_at -3.69122 0.000223 1.00E-04 0.6786 1559777_at --- --- 
207873_x_
at 
-3.55535 0.000377 1.00E-04 0.6786 207873_x_at SEZ6L chr22q12.1 
237143_at 3.55535 0.000377 1.00E-04 0.6786 237143_at --- --- 
1555243_x
_at 
3.419477 0.000627 1.00E-04 0.6786 1555243_x_at C8orf59 chr8q21.2 
220418_at 3.408154 0.000654 1.00E-04 0.6786 220418_at 
IFT52 /// 
UBASH3A 
chr21q22.3 
219134_at -3.39683 0.000682 1.00E-04 0.6786 219134_at ELTD1 chr1p33-p32 
1560661_x
_at 
3.374186 0.00074 2.00E-04 0.6786 1560661_x_at KIAA1641 chr2q11.2 
201661_s_
at 
-3.35154 0.000804 2.00E-04 0.6786 201661_s_at ACSL3 chr2q34-q35 
230319_at -3.26096 0.00111 2.00E-04 0.6786 230319_at --- --- 
242368_at -3.66858 0.000244 3.00E-04 0.6786 242368_at GTF2I chr7q11.23 
236503_at 3.464768 0.000531 3.00E-04 0.6786 236503_at 
LOC38852
6 
chr19q12 
219868_s_
at 
-3.44212 0.000577 3.00E-04 0.6786 219868_s_at ANKFY1 chr17p13.3 
211328_x_
at 
-3.2836 0.001025 3.00E-04 0.6786 211328_x_at HFE chr6p21.3 
45572_s_at 3.283603 0.001025 3.00E-04 0.6786 45572_s_at GGA1 chr22q13.31 
212480_at 3.600641 0.000317 4.00E-04 0.6786 212480_at KIAA0376 chr22q11.23 
1566094_at -3.48741 0.000488 4.00E-04 0.6786 1566094_at 
ARHGEF1
2 
chr11q23.3 
203424_s_
at 
-3.32889 0.000872 4.00E-04 0.6786 203424_s_at IGFBP5 chr2q33-q36 
207264_at -3.60064 0.000317 0.0004 0.6786 207264_at KDELR3 chr22q13.1 
221790_s_
at 
3.464768 0.000531 0.0004 0.6786 221790_s_at LDLRAP1 chr1p36-p35 
236341_at 3.453445 0.000553 0.0004 0.6786 236341_at CTLA4 chr2q33 
211219_s_
at 
-3.35154 0.000804 0.0004 0.6786 211219_s_at LHX2 chr9q33-q34.1 
221973_at 3.623287 0.000291 0.0005 0.6786 221973_at 
LOC15075
9 
chr2q11.2 
219751_at 3.453445 0.000553 0.0005 0.6786 219751_at SETD6 chr16q21 
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probeid test.stat test.p perm.p q Probe.Set.ID 
Gene 
Symbol 
Chromosomal. 
Location 
225391_at 3.419477 0.000627 0.0005 0.6786 225391_at LOC93622 chr4p16.1 
230974_at 3.419477 0.000627 0.0005 0.6786 230974_at DDX19B chr16q22.1 
242208_at 3.374186 0.00074 0.0005 0.6786 242208_at ZNF37B chr10q11.21 
210383_at -3.34022 0.000837 0.0005 0.6786 210383_at SCN1A chr2q24.3 
236436_at 3.340217 0.000837 0.0005 0.6786 236436_at 
LOC28313
0 
chr11q13.1 
204890_s_
at 
3.328894 0.000872 0.0005 0.6786 204890_s_at LCK chr1p34.3 
229495_at -3.19302 0.001408 0.0005 0.6786 229495_at ACY1L2 chr6q15 
243479_at -3.4308 0.000602 6.00E-04 0.6786 243479_at MYST4 chr10q22.2 
204204_at -3.35154 0.000804 0.0006 0.6786 204204_at SLC31A2 chr9q31-q32 
233539_at 3.328894 0.000872 0.0006 0.6786 233539_at 
NAPE-
PLD 
chr7q22.1 
200013_at 3.215667 0.001301 0.0006 0.6786 200013_at RPL24 chr3q12 
238099_at 3.193021 0.001408 0.0006 0.6786 238099_at --- --- 
205353_s_
at 
3.170376 0.001522 0.0006 0.6786 205353_s_at PEBP1 chr12q24.23 
227412_at 3.306249 0.000946 0.0007 0.6786 227412_at PPP1R3E chr14q11.2 
224162_s_
at 
3.181698 0.001464 0.0007 0.6786 224162_s_at FBXO31 chr16q24.2 
227784_s_
at 
3.170376 0.001522 0.0007 0.6786 227784_s_at COG1 chr17q25.1 
225696_at 3.102439 0.001919 0.0007 0.6786 225696_at COPS7B chr2q37.1 
225562_at 3.487413 0.000488 0.0008 0.6786 225562_at RASA3 chr13q34 
212186_at 3.419477 0.000627 0.0008 0.6786 212186_at ACACA chr17q21 
1561443_at -3.37419 0.00074 0.0008 0.6786 1561443_at --- --- 
217807_s_
at 
3.14773 0.001645 0.0008 0.6786 217807_s_at GLTSCR2 chr19q13.3 
233771_at 3.14773 0.001645 0.0008 0.6786 233771_at TRIO chr5p15.1-p14 
216100_s_
at 
-3.26096 0.00111 9.00E-04 0.6786 216100_s_at TOR1AIP1 chr1q24.2 
227177_at 3.260958 0.00111 9.00E-04 0.6786 227177_at CORO2A chr9q22.3 
239018_at 3.260958 0.00111 9.00E-04 0.6786 239018_at WBSCR18 chr7q11.23 
208714_at 3.14773 0.001645 9.00E-04 0.6786 208714_at NDUFV1 chr11q13 
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probeid test.stat test.p perm.p q Probe.Set.ID 
Gene 
Symbol 
Chromosoma
l. 
Location 
235697_at 3.14773 0.001645 9.00E-04 0.6786 235697_at ZNF544 chr19q13.43 
1555079_at -3.12508 0.001778 9.00E-04 0.6786 1555079_at C9orf68 
chr9p24.2-
p24.1 
1557258_a
_at 
-3.19302 0.001408 0.0009 0.6786 1557258_a_at BCL10 chr1p22 
216166_at 3.079794 0.002071 0.0009 0.6786 216166_at RHOH chr4p13 
234339_s_
at 
3.35154 0.000804 0.001 0.6786 234339_s_at GLTSCR2 chr19q13.3 
221780_s_
at 
3.260958 0.00111 0.001 0.6786 221780_s_at DDX27 chr20q13.13 
1552712_a
_at 
-3.21567 0.001301 0.001 0.6786 1552712_a_at NMNAT2 chr1q25 
227915_at 3.215667 0.001301 0.001 0.6786 227915_at ASB2 chr14q31-q32 
221318_at -3.1817 0.001464 0.001 0.6786 221318_at NEUROD4 chr12q13.2 
1558987_at 3.170376 0.001522 0.001 0.6786 1558987_at FLJ40473 chr3q21.3 
221966_at -3.14773 0.001645 0.001 0.6786 221966_at GPR137 
chr11cen-
q22.3 
229813_x_
at 
3.14773 0.001645 0.001 0.6786 229813_x_at DAZAP1 chr19p13.3 
234116_at -3.14773 0.001645 0.001 0.6786 234116_at CX40.1 chr10p11.21 
1563539_at -3.12508 0.001778 0.001 0.6786 1563539_at --- --- 
235784_at 3.125085 0.001778 0.001 0.6786 235784_at MTERF chr7q21-q22 
203245_s_
at 
3.260958 0.00111 0.0011 0.6786 203245_s_at FLJ35348 chr9q34 
230248_x_
at 
3.260958 0.00111 0.0011 0.6786 230248_x_at --- --- 
208875_s_
at 
-3.07979 0.002071 0.0011 0.6786 208875_s_at PAK2 chr3q29 
1561442_at -3.2836 0.001025 0.0012 0.6786 1561442_at 
LOC28358
5 
chr14q31.3 
211921_x_
at 
3.260958 0.00111 0.0012 0.6786 211921_x_at PTMA chr2q35-q36 
1563101_at -3.20434 0.001354 0.0012 0.6786 1563101_at ARNTL2 
chr12p12.2-
p11.2 
226433_at 3.204344 0.001354 0.0012 0.6786 226433_at RNF157 chr17q25.1 
222198_at -3.11376 0.001847 0.0012 0.6786 222198_at --- --- 
243854_at -3.07979 0.002071 0.0012 0.6786 243854_at APLP2 
chr11q23-
q25|11q24 
213157_s_
at 
-3.05715 0.002235 0.0012 0.6786 213157_s_at KIAA0523 chr17p13.2 
205079_s_
at 
-3.01186 0.002597 0.0012 0.6786 205079_s_at MPDZ chr9p24-p22 
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probeid test.stat test.p perm.p q Probe.Set.ID 
Gene 
Symbol 
Chromosoma
l. 
Location 
221208_s_
at 
3.306249 0.000946 0.0013 0.6786 221208_s_at C11orf61 chr11q24.2 
1558769_s
_at 
-3.26096 0.00111 0.0013 0.6786 1558769_s_at DNAH1 chr3p21.1 
1560741_at 3.170376 0.001522 0.0013 0.6786 1560741_at SNRPN chr15q11.2 
1561604_at 3.14773 0.001645 0.0013 0.6786 1561604_at --- --- 
211796_s_
at 
3.14773 0.001645 0.0013 0.6786 211796_s_at 
TRBV21-1 
/// TRBV19 
/// TRBV5-
4 /// 
TRBV3-1 
/// TRBC1 
chr7q34 
238528_at -3.12508 0.001778 0.0013 0.6786 238528_at UBR1 chr15q13 
243014_at -3.09112 0.001994 0.0014 0.6786 243014_at ZNRF3 chr22q12.1 
210757_x_
at 
-3.07979 0.002071 0.0014 0.6786 210757_x_at DAB2 chr5p13 
219947_at -3.01186 0.002597 0.0014 0.6786 219947_at CLEC4A chr12p13 
226602_s_
at 
3.011857 0.002597 0.0014 0.6786 226602_s_at 
BCR /// 
FLJ42953 /// 
LOC644165 
/// 
LOC653617 
chr22q11|22q11.
23 /// 
chr22q11.21 /// 
chr22q11.23 
240942_at -2.98921 0.002797 0.0014 0.6786 240942_at HSMPP8 chr13q12.11 
203848_at 3.193021 0.001408 0.0015 0.6786 203848_at AKAP8 
chr19p13.1-
q12 
215068_s_
at 
3.170376 0.001522 0.0015 0.6786 215068_s_at FBXL18 chr7p22.2 
224669_at 3.170376 0.001522 0.0015 0.6786 224669_at DBNDD2 chr20q13.12 
1566279_at -3.15905 0.001583 0.0015 0.6786 1566279_at --- --- 
233129_at -3.14773 0.001645 0.0015 0.6786 233129_at RYR3 chr15q14-q15 
207068_at 3.125085 0.001778 0.0015 0.6786 207068_at ZFP37 chr9q32 
225067_at 3.125085 0.001778 0.0015 0.6786 225067_at ULK3 chr15q24.1 
235322_at 3.102439 0.001919 0.0015 0.6786 235322_at 
LOC64973
4 
--- 
222668_at 3.057148 0.002235 0.0015 0.6786 222668_at KCTD15 chr19q13.11 
234106_s_
at 
-3.05715 0.002235 0.0015 0.6786 234106_s_at FLYWCH1 chr16p13.3 
205255_x_
at 
3.034502 0.002409 0.0015 0.6786 205255_x_at TCF7 chr5q31.1 
209790_s_
at 
3.011857 0.002597 0.0015 0.6786 209790_s_at CASP6 chr4q25 
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